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Abstract
NaAtm1:
Examining the mechanism of a Heavy-metal ABC Exporter
Dennis Hicks
ATP-Binding Cassette (ABC) Transporters are a superfamily of integral membrane
proteins that have been found embedded in both the cellular membranes and internal organelles of
all species yet analyzed (1). This extreme conservation throughout the tree of life is due to their
vitally critical and broad task of transporting all manner of things into and out of the cell and
related organelles. This broadness of responsibility has led to an abundant diversity of this family,
which in turn, has allowed life to adapt to the many environments found on Earth. While the
importance and variability of this family is abundantly clear, many mechanistic and regulatory
questions remain. The diversity which has made this family so useful in the natural world has
resulted in a huge challenge in the scientific world: elucidating the many mechanisms this family
has developed to perform its many functions.
The scientific community has so far been able to identify overarching features of all ABC
transporters such as the Walker A and Walker B motifs (1); however, the mechanisms of individual
transporters remain undiscovered. In my research, I focus on a specific ABC transporter called
NaAtm1 (Novosphingobium aromaticivorans ABC transporter of mitochondria 1), which has been
shown to mediate transition metal export in its host species (2). While some transition metals (e.g.
iron and copper) are essential for certain cellular processes such as respiration and enzyme
catalysis, other metals (e.g. cadmium and mercury) can be very toxic. Due to this extreme
dichotomy, a cell’s ability to distinguish between friend and foe is of the utmost importance, and
therefore is a highly regulated process.

My goal during this program was to purify NaAtm1 and create a realistic in-vitro
environment to analyze and better understand the full mechanism of this transporter, to determine
why it exports some metals while leaving others alone, and to understand the regulatory processes
that control it.
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CHAPTER 1
Introduction

In this work, the methodology to reconstitute a purified ABCB-type ATP Binding
Cassette transporter into a lipid bilayer mimetic environment is developed and optimized for use
in kinetic studies. This chapter focuses on the history and importance of ABC transporters,
transporter types and structure, as well as an overview of the protein of interest, NaAtm1.

1.1

A Brief History of ABC Transporters
The study of ABC transporters began in the late 1960’s with the study of membrane

transport systems for the uptake of nutrients in the gram-negative bacteria E. coli. At this time, all
cellular transport systems were known as permeases. Scientists divided this large group into two
smaller classes: 1) osmotic shock-sensitive transport systems and 2) osmotic shock-insensitive
transport systems.
The process of osmotic shock was first described by Harold Neu and Leon Heppel in 1965.
The process involves both a rapid change in the concentration of sucrose around a cell and the
partial destruction of the outer membrane resulting in the release of periplasmic proteins. Briefly,
gram-negative bacteria are placed in a solution that contains concentrated sucrose. The sucrose
draws water out of the cytoplasm shrinking the inner membrane and increasing the periplasmic
volume while the addition of membrane-lysing enzymes and chemicals create holes in the outer
membrane. The cells are then shifted to a solution containing no sucrose, which causes water to
rapidly enter the inner cell. This increase in cytoplasmic volume results in the rapid reduction of
periplasmic volume and pushes out many water-soluble periplasmic proteins through the lysed cell
wall [1, 2].
1

This technique of osmotic shock allowed scientists to develop the two-class theory of
shock-sensitive and insensitive permeases. Further work on these two classes led to the discovery
that the osmotic shock-sensitive nutrient permeases relied on a helper protein found solubilized
within the periplasm [3, 4]. These proteins shepherded nutrients to their respective transporters
found on the inner membrane and were later named substrate binding proteins (SBPs). It was the
resulting absence of these proteins from the expulsion of the periplasm during osmotic shock
which gave this class its name. Research also showed that this class of transporter directly derived
their energy from adenosine triphosphate (ATP) instead of from a concentration gradient, as is the
case with the osmotic shock-insensitive transport class [5]. This osmotic shock-sensitive class
would later become known as ATP-Binding Cassette (ABC) transporters.
By the early 1980’s, scientists had started cloning many genes that encoded for this class
of transporter; most notably the maltose transporter found in E. coli [6] and the histidine transporter
of S. Typhimurium [7]. At the same time, other researchers were looking into why some
mammalian cell lines –particularly certain cancer cell lines– had the unique ability to resist a wide
range of chemotherapy drugs. In 1976, researchers in Toronto discovered a large membrane
protein that was found in abundance in mammalian cells that were multi-drug resistant (MDR),
but not found in the corresponding wild-type cells (Figure 1-1). This protein was named
permeability glycoprotein (P-gp) [8] due to its ability to modulate drug permeability. Not long
after this discovery, P-gp was successfully cloned [9] and its amino acid sequence compared to
that of other transport proteins, both bacterial and mammalian.
The comparisons showed that sequences from certain sections of many transport proteins
were highly conserved. Two of the most highly conserved sequences are known as the Walker A
and Walker B motifs and were first described in ATP-requiring enzymes by Walker et al. in 1982
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[10]. These two motifs were determined to be involved in the binding and catalysis of ATP,
respectively, and were the first hints at a very distant common ancestor, both among ABC
transporters and ATP-requiring enzymes in general. Further comparisons between mammalian and
bacterial transport proteins showed that these transporters were part of a large and diverse family
of proteins [11, 12, 13], and in the early 1990’s, the term ABC transporter was coined [14].

Figure 1-1. Timeline of ABC transporter research reproduced from Theodoulou et al. [15]. Notable discoveries include
the identification of P-gp in 1976 and the cause of CFTR mis-localization (F508Δ) in 1992.

With the help of cutting-edge technologies such as genetic sequencing, X-ray
crystallography, genomic libraries, and computer data analysis and modeling, the 1990’s and early
2000’s saw an explosion of new data and discoveries regarding this family (Figure 1-1). While
these new discoveries have led to a general understanding of the overall architecture of ABC
3

transporters, many questions remain unanswered. Most studied topics relating to ABC transporters
include substrate affinity, cycle mechanisms, intra-protein and protein-protein interactions, and
transporter kinetics. These topics are of immense interest, not only for their intellectual value, but
also their practical application for human health.

1.2 ABC Transporters in human health
1.2.1 Multi-drug resistant (MDR) abilities in cancer and bacteria/fungi
It was clear early on that at least one ABC
transporter, P-gp, played a major role in multi-drug
resistant cancers within mammals (Figure 1-2). P-gp,
also known as multidrug resistant protein 1 (MDR1),
has been shown to export a wide variety of xenobiotics
from human cells, including pharmaceutical drugs [18].
While cancer cells may be sensitive chemotherapeutics,
cells that overexpress P-gp can extrude these toxic
drugs, lowering the intracellular concentration and

Figure 1-2. Structure of P-gp as reported by
Aller et al. [16]. The red portion
represents the component of Pgp surrounded by a lipid bilayer.
Image from RCSB (3G5U).

ultimately rendering the drug ineffective. These cancer cells over-expressing P- gp are rendered
multidrug resistant.

While P-gp was first found in Chinese hamsters [8], homologs have been found in both
bacteria and fungi as well [17, 18]. Due in part to the over-prescription of antibiotics and the failure
of patients to use them correctly, many strains of bacteria and fungi have been able to develop their
own version of P-gp and other MDR transporters to remove a staggeringly wide range of
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antibiotics, making the infections they cause virtually untreatable. Many scientists fear that we are
fast approaching the “post-antibiotic” era; a time at which all current antibiotics will no longer be
effective [20]. Along with antibiotic resistance, MDR presents a major hurdle in the development
of antivirals, antiparasitics, and antifungals. Fortunately, the study of ABC transporters offers a
possible solution to this challenging scenario. If scientists can elucidate the mechanisms of these
MDR transporters, they might also find a way to disable them.

1.2.2 Human ABC Transporter Related Diseases
While multi-drug resistant infections are of great importance to human health, so too is the
study of human ABC transporters. So far, about 50 human ABC transporters have been discovered
[21]. Of these, 14 have been shown to cause 13 different diseases (Table 1-1), the most notable
being cystic fibrosis.
Cystic fibrosis is caused by a point mutation in the ABCC7/CFTR transporter that is
involved in chloride ion transport in epithelial cells that are part of mucous membranes. These
membranes are abundant in the lungs, pancreas, and liver. When functioning normally, the
ABCC7/CFTR protein transports chloride ions to the cell surface. The chloride ions attract water
which results in a less viscous mucus that can be cleared from the lungs by cilia also located on
the cell surface. When the ABCC7/CFTR protein is mutated, chloride ions are unable to be
transported to the cell surface, resulting in less water accumulation and a thick mucus that is unable
to be moved by cilia and therefore accumulates within affected organs.
Symptoms of cystic fibrosis include mucus with an abnormal viscosity and sweat with a
high salt concentration [22]. These symptoms usually present in the lungs, pancreas and liver and

5

result in difficulty breathing, low amounts of digestive enzymes, and blockage of bile ducts,
respectively.

Table 1-1. List of current known diseases in which ABC transporters play a role [21]. Most notable diseases are
cystic fibrosis and Stargardt disease, caused by damaged ABCC7 and ABCA4 transporters respectively.

By understanding how these transporters work and what mutations in their structure lead
to their dysfunction, scientists may one day be able to repair them through gene editing. While this
technology is still in the very early stages of development, it has been used to treat cystic fibrosis
with some success [23].

6

1.3

Challenges in organizing the ABC transporter family
The ABC transporter superfamily is one of the largest and most diverse families of protein

in existence. They have been found embedded in both the cellular membranes and internal
organelles of all species yet analyzed [24]. This extreme conservation throughout the tree of life is
due to their vitally critical and broad task of transporting an extensive collection of molecules into
and out of the cell and related organelles. This broadness of responsibility has led to an abundant
diversity within this family, which in turn, has allowed life to adapt to the many environments
found on Earth. This same diversity has also posed an immense challenge to those seeking to
organize such a complex group of proteins for the purpose of making connections between
individual transporters and gaining significant insights regarding transporter form and function.
Before organization can begin, one needs first to understand the components that make up ABC
transporters.

1.4

Basic structure and components of ABC transporters
The typical ABC transporter consists of four core domains: two transmembrane domains

(TMD1 and TMD2) and two nucleotide binding domains (NBD1 and NBD2). These domains can
be connected in many different combinations (Figure 1-3). They can be found as four separate
subunits (tetramer), a heterodimer or homodimer consisting of one TMD and one NBD per subunit
(also known as a “half” transporter), a trimer consisting of a subunit containing two NBDs and
two TMD subunits, or a single polypeptide chain containing all four subunits [25]. While all ABC
transporters must include these four domains, some also include additional components, most
notably substrate binding proteins (SBPs) and regulatory domains.
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Figure 1-3. Various domain combinations reproduced from the HDL Handbook (Third Edition) [26]. As a rule, tetramers
and trimers are only found in bacterial ABC transporters while eukaryotic ABC transporters are made up
of either dimers or monomers.

In the following figures, the high-resolution x-ray crystallography structure of the NaAtm1
transporter is used as an example to highlight the basic domain architecture of ABC transporters
(Figure 1-4) . This transporter is the focus of this thesis, and its characteristics are explained in
greater detail at the end of this chapter.

Figure 1-4. TMDs and NBDs of NaAtm1 as reported by Lee et al. [33] NaAtm1 is a homodimer, with each monomer
(orange and green) consisting of one TMD and one NBD.
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1.4.1 The transmembrane domains (TMDs)
Transmembrane domains form the translocation pathway for substrates to move through
the membrane and are typically comprised of between 5 and 10 amphipathic helices per subunit
(10-20 helices total) [24]. This pathway is only open to one side of the membrane at a time and
access to the pathways interior is alternated through the binding and hydrolysis of ATP in the
nucleotide binding domains (NBDs).
The NBDs drive the conformational change in the TMDs through a coupling helix – a short
alpha helix found on the cytosolic side of each TMD (Figure 1-5). This coupling helix fits into a
groove in the neighboring NBD and allows for the transfer of energy to induce the conformational
change in the TMD [27]. While these coupling helices differ depending on the class of ABC
transporter, in most cases each TMD is connected to one NBD resulting in two coupling helices
per transporter.
The TMDs of ABC transporters are extremely diverse but usually share a similar topology
within the same class [28]. This diversity is most likely due to the wide array of substrates
transported by ABC transporters.

1.4.2 The nucleotide binding domains (NBDs)
The nucleotide binding domains (NBDs) are also known as ATPase domains or ATP
Binding Cassettes and give this class of transporter its name [29]. They drive the conformational
change needed to translocate substrates across a membrane through the binding and hydrolysis of
ATP and are part of the family of P-loop NTPases that depend on magnesium ions for catalysis
[30].
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There are always two nucleotide binding domains (NBD1 and NBD2) found within an
ABC transporter, with each domain consisting of two subdomains. These subdomains consist of a
RecA-like domain (found in other ATPases) and an alpha-helical domain (found only in ABC
transporters). Each subdomain in an NBD contributes to one aspect of the reaction (binding or
hydrolysis) and can only couple with the opposite subdomain on the corresponding NBD (Figure
1-5C). The functional nucleotide binding sites are located at the interface between these two
opposing subdomains.

Figure 1-5. A) Crystal structure of NaAtm1 as reported by Lee et al. [31]. B) A simplified diagram of NaAtm1showing
the four domains and coupling helices (unlabeled circles). C) A top-down view the two NBDs of NaAtm1
showing the RecA-like and α-helical subdomains.

Although there are always two NBDs and two ATP binding pockets, it is not always the
case that a transport cycle requires two ATP molecules. For example, while the OpuA transporter
hydrolyzes two molecules of ATP per substrate molecule [32], only one functioning active site is
enough to drive transport by TAP1. Interestingly, TAP1 contains a naturally occurring mutation
that results in one degenerate ATP binding site [33]. Additionally, when one site is artificially
mutated in the histidine transporter HisP2MQJ, the transporter can still function normally [34].
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While the transmembrane domains of this family are diverse, the nucleotide binding
domains show very high conservation. There are seven highly conserved amino acid
sequences/motifs in NBDs that allow for the identification of ABC transporters, as described
below. Of these seven, only the C Motif (ABC signature motif) is located in the α-helical domain;
the other six are located in the RecA-like domain. In the case of the target protein NaAtm1, all
seven sequences appear within its structure (Figure 1-6) and are highlighted in the following
figures.

Figure 1-6. Crystal structure diagram top-down view of the NBDs of NaAtm1 [31]. Each NBD contains one RecA-like
domain and one α-helical domain. Each RecA-like domain contains a Walker A motif (yellow), Walker B
motif (pink), A-Loop (black), D-Loop (red), H-Loop (magenta), and Q-loop (blue). Each α-helical domain
contains the C motif (cyan). When ATP binds on the RecA-like domain (red circle) and a substrate binds in
the substrate binding pocket (not shown), a conformational change takes place causing the α-helical domain
on the opposite NBD (blue circle) to move toward the RecA-like domain, sandwiching the ATP between the
two and allowing hydrolysis to take place.
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1.4.2.1 Walker A Motif (P-loop)
The Walker A motif connects an α-helix and a ß-strand to form a pocket for ATP binding
within its NBD [35]. The consensus sequence for this motif varies slightly depending on the
source.

The

most

common

sequences

are

GXXXXGKS

[36],

GXXGXGKS

[37],

(G/A)XXXXGK(T/S) [10], and GXXGXXK [38]. The X residues in these sequences signify highly
variable amino acids.
The most highly conserved residues in this motif are the N-terminal glycine and the Cterminal lysine. The lysine has been shown to bind to the γ-phosphate of ATP and in some cases
is replaced by an arginine which can lower the activity [39]. A serine or threonine usually follows
the highly conserved lysine and provides a hydroxyl group to bind the divalent cation associated
with the bound nucleotide [40]. In NaAtm1, this sequence starts at residue 349 and ends at 401
(Figure 1-7). The sequence is GPSGAGKS and ends in a serine (S401) [31].

Figure 1-7. Cartoon diagram side view of the NaAtm1 Walker A motif (yellow) with the highly conserved residues
glycine (G394), lysine (K400), and serine (401) as reported by Lee et al. [31].
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1.4.2.2 Walker B Motif
The Walker B motif coordinates the magnesium ion needed for catalysis. This ion interacts
with the ß- and ɣ- phosphates of ATP and helps to both stabilize and hydrolyze ATP. The general
consensus sequence for this motif is hhhhD(E) and consists of three components: four hydrophobic
residues (h) followed by an acidic negatively charged residue (usually aspartic acid) and then a
second acidic residue (usually glutamic acid). The second acidic residue (E) is commonly included
in the D-loop conserved sequence which immediately follows the Walker B motif. The aspartic
acid is believed to play a role in coordination of the magnesium ion while the acidic residue
immediately following it acts as a general base, polarizing an attacking water molecule involved
in the hydrolysis of the ɣ- phosphate in ATP [41]. In NaAtm1, this sequence starts at residue 518
and ends at 522 (Figure 1-8). The sequence is ILLFD(E), with the (E) overlapping into the Dloop.

Figure 1-8. Cartoon diagram side view of the NaAtm1 Walker B motif (pink) with the highly conserved residue aspartic
acid (D522) as reported by Lee et al. [31].
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1.4.2.3 A-loop
The A-loop is composed of a single aromatic residue that helps position the ATP through
stacking with the adenine ring of ATP [42]. This residue generally appears around 25 amino acids
upstream from the Walker A motif. In NaAtm1, the A-loop consists of a tyrosine 24 AA upstream
(Y370) (Figure 1-9).

Figure 1-9. Cartoon diagram side view of the NaAtm1 A-loop (black) with the aromatic residue tyrosine (D522) as
reported by Lee et al. [31].
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1.4.2.4 C Motif (ABC signature motif)
This sequence is a signature of ABC transporters and is not found in other P-loop NTPases
and has a consensus sequence of LSGGQ. It is found in the α-helical subdomain and has been
shown to interact with the RecA-like domain on the opposing NBD to form a binding pocket. The
serine (S499) in this motif interacts through its oxygen with the ɣ- phosphate of ATP [43]. This
interaction may draw these two subunits together causing a conformational change in the NBDs
(going from an open position to a closed position) which results in a conformational change of the
TMDs. In NaAtm1 this sequence starts at residue 498 and ends at 502 (Figure 1-10). This motif
is slightly different than normally reported with a sequence of LSGGE.

Figure 1-10. Cartoon diagram side view of the NaAtm1 C Motif (cyan) with the active residue serine (S522) as reported
by Lee et al. [31].
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1.4.2.5 D-loop
The D-loop is a sequence that immediately follows the Walker B motif and has a consensus
sequence of SALD or EATSALD (overlapping Walker B) depending on the source. In the
EATSALD sequence, the E corresponds to the second acidic residue in the Walker B motif,
glutamate. While this glutamate is involved in polarizing the catalytic water molecule in the active
site, the aspartic acid on the opposite end (D529) interacts with the P-loop (Walker A Motif) of
the opposing active site [44]. This interaction between the D-loop on one NBD and the P-loop of
the opposite NBD is believed to allow communication between the two active sites [45, 46]. In
NaAtm1 this sequence starts at residue 523 and ends at 529 (Figure 1-11). The sequence is
EATSALD.

Figure 1-11. Cartoon diagram side view of the NaAtm1 D-loop (red) with the active residues glutamic acid (E523) and
aspartic acid (D529) as reported by Lee et al. [31].

16

1.4.2.6 H-loop
The H-loop consists of a highly conserved histidine residue that forms a “hinge” or “lynchpin”
between an α-helix and a ß-sheet. Until recently, it was thought this residue acted as a non-reactive
“lynchpin” that only coordinated the aspartate at the end of the D-loop, the glutamate at the
beginning of the D-loop/end of the Walker B motif, the ɣ- phosphate on ATP, and the magnesium
ion through hydrogen bonding. New research suggests however that this residue also acts as a
proton transfer point by acting first as a general acid, and then as a general base during ATP
hydrolysis [47]. In NaAtm1 this residue is H554 (Figure 1-12).

Figure 1-12. Cartoon diagram side view of the NaAtm1 H-loop (magenta) with the highly conserved residue histidine
(H554) as reported by Lee et al. [31].
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1.4.2.7 Q-loop
The Q-loop consists of a highly conserved glutamine found at the junction of the two NBD
subdomains and has the consensus sequence XXQXX where X represents any amino acid. The Qloop is the main interface between the NBD and TMD and its conformational changes allow the
conserved glutamine to form an active site when ATP is bound and to disrupt the active site when
ATP is hydrolyzed [29]. In NaAtm1 this sequence starts at residue 440 and ends at 444 (Figure 113). The sequence is VPQDS.

Figure 1-13. Cartoon diagram side view of the NaAtm1 Q-loop (blue) with the highly conserved residue glutamic acid
(Q442) as reported by Lee et al. [31].
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1.5

Accessory Domains
Accessory domains are transporter components that are not ubiquitous to all transporters -

indeed, the protein of interest in this thesis, NaAtm1, contains none of these- but when present,
play an important role in protein function. These domains can be found separate from, attached to,
or integrated in a transporter. These domains have been divided into four categories based on
location and function [48]. They are: extracytoplasmic domains, membrane-embedded domains,
cytosolic regulatory domains, and cytosolic catalytic domains.

1.5.1 Extracytoplasmic domains
These domains are found on the N-terminal (extracellular) end of transporters or in the
periplasm. There are three subgroupings of this domain: large extracytoplasmic domains (ECDs),
the N-terminal domains of ProW and ProU, and the substrate binding proteins (SBPs) found in
prokaryotes [48]. For purposes of simplicity, only substrate binding proteins (SBPs) will be
discussed in this paper.
ABC transporters that import substrates require Substrate Binding Proteins (SBPs) to act
as substrate shepherds. These proteins capture substrate and deliver it to the cytoplasmic side of
the TMDs. SBPs can be tethered to the ABC transporter, anchored to the membrane, or free
floating in the periplasm (only found in gram negative bacteria). These proteins have been shown
to be monomers with one binding site per SBP [49].
SBPs are generally composed of two lobes connected by hinge (although there are threelobed SBPs, of which the third lobes function is not known [50]) (Figure 1-14). This hinge allows
the two lobes to enclose a substrate similar to the way a Venus flytrap catches its prey [51]. The
importance of the SBPs will be discussed in the context of transport mechanisms in Section 1.9.
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Figure 1-14. Crystal structure of the substrate binding protein (SBP) BtuF with vitamin B12 bound as reported by Borths
et al. [52]. The two lobes (blue and red) are attached to a hinge (green) that allow them to enclose the
substrate vitamin B12.

1.5.2 Membrane-embedded domains
This set of accessory domains consists of the extra transmembrane helices seen in many
transporters that are not part of the “core” TMDs (i.e. helices that do not help form a translocation
pathway). While the function of many of these are unknown, some are proposed to act as anchors
for SBPs [53].

1.5.3 Cytosolic regulatory domains
These accessory domains are found on the cytosolic side of the membrane and are used to
regulate the activity of the transporter as well as transcriptional regulation. The mechanisms of
regulation vary by transporter and type of regulation. These regulations allow for the fine tuning
of nutrient uptake or product/waste expulsion within a cell. An example of this regulatory domain
can be found within the methionine importer of E. coli, MetNI. In this importer, methionine is both
a substrate and inhibitor, preventing the build-up of excess methionine within the cell.
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1.5.4 Cytosolic catalytic domains
In some cases, the accessory cytosolic domain has a catalytic purpose. In the type I
secretion pathway, ABC transporters not only transport polypeptides targeted for export but have
the additional job of removing the leader peptides that denoted export as well. The signal sequence
in this case has a consensus sequence of LSXXELXXIXGG and is cleaved after the two conserved
glycine residues [54].

1.6

ABC transporter classes
The superfamily of ABC transporters is just that – a superfamily – and it can be a challenge

to divide such a large and diverse set of proteins. While all ABC transporters contain a core of four
domains (two NBDs and two TMDs), their cellular function allows for broad categorization. To
start, we can differentiate between importers, exporters, and non-porters. These groupings can be
further subdivided through structural homology, sequence similarity, and functional similarity.

1.7

ABC importer classes and proposed mechanisms
ABC importers are a group of ABC transporters that, as the name suggests, bring needed

materials into a cell and, with very few exceptions, are only found in bacteria and archaea [55].
Substrates include sugars, peptides, proteins, sterols, lipids, and ions. The majority of these
importers require a substrate binding protein (SBP) to function properly (part of the
extracytoplasmic accessory domains as described above). These SBPs led to the discovery of this
family (part of the osmotic-shock sensitive transport systems as described in the introduction). In
this class, the four core domains are only found as either a tetramer (as in the Nik, Mal, and Btu
systems), a fused TMD with two NBDs (Fhu), or two TMDs with a fused NBD (Rbs) (Figure 1-
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15) [48]. Importers can also be subdivided based on their functionality into three subgroups: Type
I importers, Type II importers, and Type III (ECF) importers.

Figure 1-15. Cartoon drawing of the different core arrangements for the importer class of ABC transporter adapted
from Biemans-Oldehinkel et al. [48].

1.7.1 Structure of Type I and II importers
While these two types of importer are very similar in terms of composition and topology,
structural and mechanistic features divide them into two separate groups. Structurally, Type I
importers have a core of 5 transmembrane helices per TMD and commonly contain additional
TMD helices that wrap around its partner TMD (10-16 helices total, see Figure 1-16) [29]. The
two TMDs of the Type I importer face each other and the translocation pathway is found between
them. Type II importers have 10 helices per TMD (20 total), and do not contain any helices that
wrap around the partner TMD. These two TMDs are lined up, side-to-side facing opposite
directions.
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Figure 1-16. Top-down view of the TMDs from a Type I and Type II importer. A) MalF and MalG TMD subunits of the
Type I transporter MalEFGK2 [56]. B) BtuC dimer of the Type II transporter BtuC2D2F [57].

In addition to the different TMD arrangements, Type I importers such as MalFGK2 contain
a substrate binding site within their TMDs (not to be confused with a Substrate Binding
Protein) while Type II importers do not. This is probably due to the types of substrates each
importer type transports as well as potential mechanistic differences between the two. Type I
importers generally only handle small molecules such as ions, small peptides, amino acids, and
mono-/oligosaccharides [58]. It is possible these small molecules have more room to move (and
escape) while in the translocation pathway, and the presence of a substrate binding site ensures
that the transport process is efficient by providing a checkpoint for regulation; if no substrate is
bound to the substrate binding site, ATP hydrolysis will not proceed. In contrast, Type II importers

23

handle large complex molecules such as vitamin B12 and heme, as well as inorganic ions [58]
which may have a lesser chance of escaping the translocation pathway.
Both the Type I and Type II importers contain an extracytoplasmic accessory domain: a
substrate binding protein (SBP) to shepherd substrates to their N-terminal openings. These
domains can be soluble within the periplasm (found in gram-negative bacteria), attached to the
cytoplasmic membrane either by a “lipid anchor” (gram-positive bacteria) or a transmembrane
peptide (archaea), or directly fused to one of the TMDs (resulting in two SBPs per importer) [48]
(Figure 1-17). In the glutamine-glutamate transporter system, GlnPQ, two SBPs are fused to a
single TMD resulting in four SBPs per importer [59].

Figure 1-17. Cartoon drawing of the different types of Substrate Binding Proteins (SBPs) reproduced from BiemansOldehinkel et al. [48].

1.7.2 Possible mechanisms of Type I and II importers
While these two importer types contain similar core domains along with an SBP, an
increasing number of studies have demonstrated a diversity of transport mechanisms. The two
prevailing models for ABC importers are described below.
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An impressive body of structural studies on the maltose transport system (MalFGK-E) and
vitamin B12 system (BtuCD-F) has provided evidence in support of an alternating access model for
transport [60 and 61]. In this model there are four general steps in the catalytic cycle, however
slight variations have been shown between different transporters (Figure 1-18).

Figure 1-18. The alternating access model for transport. This process starts at the center top and moves clockwise.

The cycle starts when a ligand-loaded substrate binding protein binds to the TMDs of the
transporter that is in a “resting state” (referred to as the “inward facing conformation”) with the
energy source ATP absent from the ATP active sites (Figure 1-18, top). The binding of the ligandloaded SBP brings the NBDs closer which promotes ATP binding. In the second step, the binding
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of ATP triggers coordinated conformational changes in the TMDs, SBP and NBDs. In the TMDs,
the conformational change results in opening of the translocation pathway to the periplasm (the
“outward facing conformation”). In the SBP, the conformational change of the TMDs result in the
release of the ligand into the translocation pathway, where the ligand binds to the substrate binding
site. In the NBDs, the ATP-filled active sites come close enough for hydrolysis to occur. In the
third step ATP hydrolysis occurs; the hydrolyzed ATP (now ADP and Pi) cause the transporter to
return to the resting state (inward conformation) which results in the opening of the NBDs, release
of the ligand into the cytosol, and the release of the now empty SBP. The fourth step consists of
the release of ADP from the active sites to reset the cycle.
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Figure 1-19. A second model for transport, based on the vitamin B12 importer, BtuCD-F [58].

A second “non-canonical” mechanism for transport is based on functional assays and, most
recently, mass spectrometry [58, 62, 63]. In this model, the cycle starts with the transporter in a
resting state (partially outward conformation) with no ATP bound and the substrate binding protein
firmly bound (Figure 1-19, top). The binding of one ATP molecule increases the affinity of a
second ATP binding and the presence of two ATP molecules partially destabilize the SBP by fully
opening the TMD (outward conformation). This destabilization allows for the ligand to fit in
between the SBP and the transporter translocation pathway. Although the TMDs do not have a
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substrate binding site, the partial insertion of the ligand into the translocation pathway results in
the NBDs coming close enough for hydrolysis to occur. The hydrolysis results in the opening of
the NBDs (inward conformation), release of the substrate, and the re-binding of the SBP [58]. The
now-hydrolyzed ATP (ADP + Pi) are then released and the cycle is reset.
Interestingly, both of these models have been developed based on work from the same
transport systems, mainly MalFGK-E and BtuCD-F. Support for the alternating access model is
driven by the high-resolution crystal structures of several intermediate states throughout the
transport cycle. The non-canonical model, in contrast, is based on functional studies including
thermodynamic, kinetic, and mass spectrometry experiments. The techniques and experimental
conditions for these studies are fundamentally different, and their conflicting conclusions remain
to be resolved.

1.7.3 Structure of Type III (ECF) importers
If the Type I and II importers are considered fraternal twins, the Type III importer can be
considered the weird younger brother who may or may not be the milkman’s. This class of
transporter is also known as an energy coupling factor (ECF) type ABC transporter. While the
Type I and II importers have a pair of transmembrane domains that form a translocation pathway
for the substrate, Type III importer architecture is significantly different. Type III importers consist
of two distinct integral membrane proteins: (1) a substrate-binding component (or S-component)
with high substrate specificity and (2) a transmembrane component (or T-component) that
transfers the energy from the NBDs [64]. The three-component complex consisting of the Tcomponent and two NBDs is known as the ECF module. The Type III importer can itself be broken
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into two subgroups based on chromosomal location of the genes that encode these two
components: ECF group I and ECF group II [65].

1.7.3.1 Differences between ECF subgroups I and II
Members of the ECF group I importers have genes that code for the S-component and ECF
module on the same operon which are thought to form a dedicated complex (i.e. a complex that
does not dissociate). In contrast, members of the ECF group II have genes for the ECF module
separate from multiple S-components that have different substrate specificities. These Scomponents are thought to form interchangeable complexes with a single ECF module. This
modular system is an interesting departure from the Type I and Type II import systems and
potentially streamlines the number of protein components needed for uptake of different
substrates.

1.7.3.2 Type III substrates
The Type III importers have been shown to have high specificity for vitamins or vitamin
precursors including pantothenate, pyridoxine, thiamine and its precursors, methionine, cobalamin
precursors, queuosine, lipoate, niacin and folate [65]. In total, the S-components have been
classified into 21 protein families, which are associated with either ECF group I or group II Tcomponents (Figure 1-20). Some S-components form complexes with both dedicated and shared
ECF groups.
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Figure 1-20. A list of known dedicated (green) and shared (pink and tan) Type III ECF transporters (bold) and their
substrates [65].

1.7.4 Type III transport mechanism
What is truly unique about this transporter is the movement of the S-component within the
lipid bilayer. Crystal structures have shown that while solitary S-components have substrate
binding sites close to the extracellular side of the membrane, the S-component can lie parallel to
the lipid bilayer with its binding site exposed to the cytosol when in complex with the ECF module.
This suggests that the re-orienting of the S-component plays a role in substrate transport (Figure
1-21) [65].
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Figure 1-21. A proposed mechanism for the ECF-type transporter [61].

This mechanism varies slightly between Group I and Group II proteins only in that the Scomponent is interchangeable in group II. The first step in the Group II mechanism is the joining
of a ligand-bound S-component and a free ECF module into a full complex.

1.8

ABC exporters
ABC exporters are found in all lifeforms yet studied. They are located on the cellular

membrane of both prokaryotic and eukaryotic species as well as in organellar membranes of
eukaryotic species including the ER, inner mitochondrial membrane, peroxisomal membrane, and
vacuolar membrane [48]. ABC exporters do not require a SBP to function as is the case with the
Type I and II importers. While many importers are found a tetramers or trimers, ABC exporters
are almost exclusively found as “half transporters” (a pair of polypeptides that each contain one
TMD and one NBD) or “full-length transporters” (a single polypeptide containing two TMDs and
two NBDs).
As previously stated, ABC importers are, with very few exceptions, found only in
prokaryotic life. This means that eukaryotes only possess ABC exporters and therefore the exporter
group of ABC transporters is usually referred to as the eukaryotic group of ABC transporters, even
though members of this group are also found in prokaryotes. This group has been broken into
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seven families based on domain organization and primary structure similarity [66]. These families
are ABCA, ABCB, ABCC, ABCD, ABCE, ABCF, and ABCG. For simplicity, the descriptions
below focus on the human members of these families.

1.8.1 ABCA Transporters
The ABCA family was first described in 1994 by Luciani et al. [67] and consists of twelve
known members in humans. This group of transporters has been shown to be involved in lipid
transport and some members are hypothesized to be involved in pulmonary surfactant secretion
and macrophage lipid homeostasis.

1.8.2 ABCB Transporters
The ABCB family consists of eleven known members, seven of which are “half
transporters” and is the only family that contains both “half transporters” and “full transporters”.
This family contains the most famous of human ABC transporters – ABCB1. This transporter,
more commonly known as P-gp, acts as a localized general drug exporter and confers multi-drug
resistance (MDR). Some members of this family participate in the secretion of
phosphatidylcholine, cholesterol, and bile salts, while others are found in the mitochondria and are
involved in iron/sulfur synthesis and transport [66].

1.8.3 ABCC Transporters
This family contains twelve known human “full transporters” which are involved in drug
resistance, ion transport, nucleoside transport, and signal transduction. The most highly-studied
transporter in this family is the ABCC7 transporter, also known as CFTR. This modified
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transporter acts as a chloride ion channel and results in cystic fibrosis when deformed or absent.
While there are many mutations that cause the CFTR protein to fail, the majority of those suffering
from cystic fibrosis have a mutation that causes misfolding in the protein that keeps it from
localizing to the cell surface.

1.8.4 ABCD Transporters
This family contains four genes that encode “half transporters”, all of which are expressed
only in the peroxisome. Recent studies suggest that these subunits can mix and match and might
be linked to fatty acid metabolism. It has been shown that ABCD1 plays a role in the X-linked
form of adrenoleukodystrophy (ALD) which is characterized by cells with an excess of unbranched
saturated fatty acids [66].

1.8.5 ABCE Transporters
There is currently only one human member of this family: ABCE1. It is considered a nonporter due to the absence of a transmembrane domain. It is made up of two NBDs and an Nterminal Fe-S binding domain. This protein inhibits a nuclease induced by interferon in
mammalian cells. It also has been shown to play a role in vertebrate translation initiation. ABCE1
is found in all characterized eukaryotes and archaea [68].

1.8.6 ABCF Transporters
There are three known human genes that encode 26 different known proteins for this
family. Like the ABCE transporters, these proteins lack any TMDs and are considered non-porters.
Many of the ABCF transporters are thought to play a role in inflammatory processes [69].
33

1.8.7 ABCG Transporters
This transporter class is unique in that it contains five genes that encode six reverse “half
transporters”. These subunits contain a NBD at the N-terminus and a TMD and the C-terminus—
the reverse of all other ABC genes. This family was first reported in Drosophila White (whiteeyed mutant fruit fly) and is known as the “White Half Transporters” [70]. In Drosophila White,
this first protein (white) found in white-eyed males can combine with two other proteins (brown
and scarlet) to form heterodimers which transport guanine and tryptophan respectively to the eye
cells and result in the eye color. While these proteins play a role in eye pigment in flies, in humans
they seem mainly involved in the transport of dietary sterols and cholesterol transport regulation
[71].
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1.8.8 Proposed mechanism of exporters
The proposed general mechanism for exporters is similar to that of the canonical alternating
access model (Figure 1-22). In the case of exporters, the resting state is in an inward conformation.
The substrate binds at a substrate binding site in the TMDs, followed by the binding of two ATP,
or vice versa. The binding of substrate and ATP triggers a conformational change in the TMDs to
the outward conformation. The substrate is released to the exterior of the cell, and ATP is
hydrolyzed. The hydrolysis of the ATP resets the transporter back to the resting state [72].

Figure 1-22. Drawing of a proposed exporter mechanism [72].
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1.9

ABC non-porters
Some proteins that contain both the Walker A and B motifs, as well as the ABC signature

motif are known to carry out other functions than transport. These types of “transporters” usually
do not contain a transmembrane domain such as the members of the eukaryotic groups ABCF and
ABCG. Many of these proteins such as Rad50 play a role in regulation and DNA repair [73]. Due
to the non-transporter-like nature of these proteins, they will not be discussed in depth.

1.10

Protein of interest: an ABC exporter found in mitochondria
This thesis focuses on a member of the ABCB exporter family found in mitochondrial

membranes. The first homolog of this exporter was discovered in the inner membrane of
mitochondria of Saccharomyces cerevisiae and was named Atm1p (ABC transporter of
mitochondria 1) [74]. Initial studies of Atm1p showed that the disruption of this transporter in vivo
led to very slow growth on rich media and no growth on minimal media. Further experiments with
Atm1p showed that the mitochondria lacked mature cytochromes (i.e. cytochromes that contained
a covalently bonded heme group) and that heme-containing proteins outside the mitochondria were
also affected in the same way. After ruling out other factors such as impaired heme attachment
reaction pathways and biosynthetic pathways, it was determined that Atm1p plays a critical role
in the maturation of heme-containing proteins within the cell [75].
Researchers then looked for what substrates might be transported by Atm1p and found that
in mitochondria that lacked functioning Atm1p, their “free” iron (iron not bound to heme or Fe-S
clusters) was 30 times greater than that of wild-type mitochondria. Of this, only a small fraction
was in a state that could be readily used for the synthesis of heme and Fe-S clusters. This suggested
that Atm1p mediates iron homeostasis, and that iron—or more likely an iron containing complex—
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might be a natural substrate [75]. While the identity of Atm1p’s natural substrate remains unclear,
likely candidates include Fe-S complexes and heme (or some intermediate). The creation of these
cytosolic heme and iron sulfur cluster containing proteins are critical in many cellular processes
such as DNA synthesis and respiratory electron transfer chains. Due to this role in the maturation
of iron-containing proteins that are essential to cellular function, this is the only known eukaryotic
ABC transporter that is essential for cell growth [75].
Atm1p homologs have since been characterized in several other species, including ABCB6
and ABCB7 in humans and HMT1 in multiple species. In humans, the ABCB7 transporter plays
a role in transition metal homeostasis and iron-sulfur cluster maturation in the cytosol [76] while
the ABCB6 transporter may play a role in arsenic resistance [77]. When ABCB7 is damaged, it
results in X-linked sideroblastic anemia which is associated with spinocerebellar ataxia
accompanied by severe cerebellar hypoplasia [78]. In both C. elegans and D. melanogaster, HMT1
confers resistance to cadmium [79, 80].
In many of these homologs, the polypeptide glutathione (GSH, γ-Glu-Cys-Gly) has been
shown to play a role in transport of substrates (Figure 1-23) [81], although the mechanism of this
dependence is unclear. Glutathione is a key antioxidant and helps confer resistance to heavy metals
and xenobiotics [82, 83] so it is plausible that GSH acts as a co-substrate for Atm1p homologs,
with an affinity for a wide array of toxic materials as well as the ability to stimulate these
transporters.

Figure 1-23. Molecular structure of GSH.
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1.10.1 Atm1 in Novosphingobium aromaticivorans
The focus of this work is on the Atm1p homolog
found

in Novosphingobium

aromaticivorans

(Novosphingobium aromaticivorans ABC transporter of
mitochondria 1). This species was first classified by
Takeuchi et al. in 2001 [84] and is an aerobic gram-negative
bacterium that can break down phenolic structures. It has
also been implicated in biliary cirrhosis in humans due to its

Figure 1-24. Microscopic image of N.
Aromaticivorans [82].

ability to express proteins similar to human proteins that
trigger T cell-mediated tissue destruction [86].
NaAtm1 was structurally and functionally characterized by Lee et al. in 2014. The highresolution crystal structure of NaAtm1 shows a homodimer “half transporter” in the inward
conformation (Figure 1-25). It has a total of 6 TMD helices per half and is roughly 120Å x 85Å in
size. Initial studies have shown that NaAtm1 shares ~45% sequence identity to the homologs
ABCB7, HMT1, and yeast Atm1 [31]. Five different crystal structures for this protein have been
reported (4MRN, 4MRP, 4MRR, 4MRV, 4MRS) with each crystal structure containing a different
bound ligand (Apo, Reduced glutathione (GSH), Selenomethionine, S-Mercury glutathione, and
Oxidized glutathione (GSSG) respectively) [31].
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Figure 1-25. Dimension of NaAtm1 along with locations of the primary (red) and secondary (black) substrate binding
sites as reported by Lee et al. [31].

1.10.2 NaAtm1 substrate binding sites
Crystal structures have revealed two substrate binding sites (SBSs), with the main SBS
located about 5Å into the transmembrane region. The second lower affinity site is located about
5Å below the primary binding site. The primary binding site is formed by Asp316, Gly319, and
Met320 from TMD6/TMD12 and Asn296 and Gln272 from TMD5/TMD11, while the secondary
binding site is comprised of Arg206, 210 and 323.

Figure 1-26. A) Primary binding site bound with the substrate S-Hg(GSH)2 B) Secondary binding site bound with the
substrate GSSG, as reported by Lee et al. [31].
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The relevance of these two sites is not yet fully understood; however, the relative
orientation could accommodate a glutathione complexed iron-sulfur cluster ([2Fe:2S](GS-)4)
(Figure 1-27) complex [31].

Figure 1-27. Structure of a glutathione complexed iron-sulfur cluster ([2Fe:2S](GS-)4). This may be a possible
substrate that can interact with both binding pockets found within NaAtm1.

1.10.3 In vitro characterization of NaAtm1 activity
In addition to structural studies, preliminary kinetic assays revealed that NaAtm1 has a
high affinity for the transition metals silver and mercury in complex with glutathione (Table 1-2).
Substrates that do not include glutathione did not stimulate activity in this transporter, consistent
with studies using homologs of NaAtm1 [78]. Interestingly, while it is accepted that GSH is a
critical component involved in transport, reduced glutathione (GSH) stimulated relatively low
transporter activity compared to oxidized glutathione (GSSG). This suggests that the natural
substrate of NaAtm1 contains more than one GSH, as shown in the binding of S-Hg(GSH)2 (Figure
1-26A).
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Table 1-2. Kinetic constants for the ATPase activity of substrates in NaAtm1 as reported by Lee et al. [31]

To demonstrate that substrate was transported across a lipid bilayer, proteoliposomes
containing reconstituted NaAtm1 was assayed. In the presence of wild-type NaAtm1
proteoliposomes and ATP, increasing amounts of GSSG accumulated within the proteoliposomes
as a function of time. These results indicated that the increased ATPase activity of NaAtm1
correlated with transport of substrate across a lipid membrane.

1.10.4 In vivo functionality of NaAtm1
To test if NaAtm1 exports the substrates silver and mercury in vivo, metal sensitive strains
of E. coli were grown and subjected to metal salts (CuSO4, ZnSO4, CdCl2, AgNO3, and HgCl2).
No protection was observed against Cu2+, Zn2+, or Cd2+, however protection was conferred by
NaAtm1 for Ag2+ and Hg2+. These results suggest that Ag2+ and Hg2+ are capable of being exported
by NaAtm1 and therefore prolong the survival of an organism in the presence of these toxic
metals.
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1.11 Studies presented in this work
This thesis describes the development and optimization of an NaAtm1 lipid bilayer system
designed for in vitro studies of transport. In Chapter 2, the general principles behind protein
purification are described, followed by procedures and results for three different proteins. Chapter
3 introduces the different lipid mimetic environments used in the study of ABC transporters. This
chapter details the experiments and findings for the reconstitution of NaAtm1 into a lipid lipidfilled structure referred to as a nanodisc. In Chapter 4, data from preliminary kinetic studies are
presented, and future directions are discussed.
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CHAPTER 2
Protein Purification

When studying protein function from a biochemical perspective, an essential first step is
to isolate the protein of interest. The resulting protein must be reproducibly purified to a single
species with high yield. During my time at USF I have developed and improved multiple protein
purification methods for the purpose of purifying both single proteins (NaAtm1, MSP1D1, and
TEV protease), as well as protein complexes (NaAtm1 reconstituted into nanodiscs). This chapter
outlines the theories behind the primary techniques routinely employed during purification.
Additionally, key specialized instruments for protein purification are described. Lastly, the
methods used in the expression and purification of NaAtm1 and the accessory proteins MSP1D1
and TEV protease are detailed. The purpose of the accessory proteins MSP1D1 and TEV protease
will be described in Chapter 3.

2.1 Method theories
While the process of protein purification employs a myriad of materials and techniques,
this section will focus on two chromatography-based techniques used for preparative purposes and
one technique employed for analysis. The two chromatographic methods are immobilized metal
affinity chromatography (IMAC) and size exclusion chromatography (SEC). Both types of
chromatography are performed using an FPLC (Fast Protein Liquid Chromatography) instrument
which is described later in this chapter. These chromatography methods are paired with an analysis
method called sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) which is
used to assess the purity of a protein sample.
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Chromatography: “A process in which a chemical mixture carried by a liquid or gas is separated
into components as a result of differential distribution of the solutes as they
flow around or over a stationary liquid or solid phase” [1].

2.1.1 Immobilized metal affinity chromatography (IMAC)
IMAC is a method of chromatography that uses a metal (typically nickel or copper) that
has been immobilized to bind proteins of interest. IMAC was first developed by Porath et al. in
1975 as a novel way to separate proteins [2]. Originally, iminodiacetic acid (IDA) was used as a
metal immobilizer, however due to its weak binding of metals, a more effective immobilizer was
developed by Hochui et al. in 1987 [3] (Figure 2-1). This new immobilizer – Nitrilotriacetic acid
(NTA) – had the ability to bind to four of the six binding sites found in the coordination sphere of
a nickel ion rather than the three sites bound by IDA [4]. Commercial IMAC columns use
nitrilotriacetic acid-bound nickel, referred to as Ni-NTA columns.

Figure 2-1. Comparison of the NTA and IDA immobilizers interacting with nickel ions [4]
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2.1.1.1 Poly-histidine tags
To selectively interact with the nickel ion described above, proteins of interest are
genetically modified to add a “His-tag”. His-tags were first described by Hochuli et al. in 1988 [5]
and are comprised of 6-10 histidine residues that have been placed at either the N- or C-terminus
of the protein of interest. For many proteins, protein folding and function are not significantly
affected by the addition of a His-tag to one of the termini. Multiple histidine residues are introduced
because the imidazole group on the side chain exhibits the highest affinity for metal ions of all the
amino acids [6] (Figure 2-2). Purification using a His-tagged protein and Ni-NTA can increase
target protein purity from less than 1% to up to more than 95% purity [4].

Figure 2-2. A nickel-loaded Nitrilotriacetic acid (Ni-NTA) (blue) bound to resin (blue sphere) binding to part of a polyhistidine tag (green) [7].

Once bound, the resin can be washed with the low concentrations of imidazole (10-50 mM)
to remove any impurities, followed by elution from the column at higher concentrations (300-500
mM). IMAC is routinely chosen as a primary purification method because it is robust, relatively
inexpensive, and can be used with a wide variety of buffer conditions.
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2.1.2 Size exclusion chromatography (SEC)
Size exclusion chromatography is based on the use of a porous matrix to separate a
mixture of particles by their molecular weight. In this porous matrix, smaller components of a
mixture take longer to travel through the column than larger components. This is because the
smaller components are able to fit into a larger percentage of pores and are temporarily impeded.
This idea was first postulated by Synge and Tiselius [8] based on zeolite research by R. M. Barrer
[9]. The first columns were packed with potato or maize starch, which have a very low adsorption
of proteins [10]; however, they were not strong enough to withstand high linear velocities. Today,
the most commonly used packing materials (referred to as size exclusion media) are small porous
spheres made up of either cross-linked composite dextran, agarose, or polyacrylamide (Figure 23) [11].
One way to understand this somewhat counter-intuitive technique is to imagine the size
exclusion column and its resin as a large hollow cylinder filled with whiffle balls. If a mixture of golf
balls and marbles were placed onto the top of this column, the marbles would be able to enter the
whiffle balls while the golf balls could not – they would have to go around the whiffle balls. In this
scenario the marbles have a longer path length through the column due to continually entering
and exiting the interior of the whiffle balls. This results in the golf balls (the larger component of
the mixture) to come out of the bottom of the cylinder first. Likewise, in size exclusion
chromatography, the largest protein components are eluted first.
One important feature of a SEC column is its void volume. The void volume of a column
is the volume at which an unretained molecule elutes. To extend the analogy above, the golf balls,
which do not get stuck in any whiffle balls, would elute at the void volume. Protein molecules
eluting at the void volume are larger than what the column can resolve and are most commonly
very large protein aggregates.
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Figure 2-3. A) Sample of a size exclusion bead interacting with three different sized molecules. B) A size exclusion
column at different times (column 1 = T0, 2 = T1, 3 = T2). The colors correspond to the different components
of the mixture. C) A sample chromatogram showing the elution order of largest to smallest [12].

While IMAC can yield a relatively pure sample enriched with the His-tagged protein, the
elution may also contain aggregates and other impurities. Size exclusion chromatography can
remove these impurities if the sizes are within the resolution ability of the resin.
2.1.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
Electrophoresis: “The movement of suspended particles through a medium (such as paper or
gel) under the action of an electromotive force applied to electrodes in contact
with the suspension” [13].

SDS-PAGE is a method of electrophoresis created by U.K. Laemmli in 1970 [14] that
denatures proteins using sodium dodecyl sulfate (SDS) and then separates them based on
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molecular mass by passing them through a polyacrylamide gel [15]. Polyacrylamide is used
because it is chemically inert and produces different pore sizes at different concentrations.

Figure 2-4. Components and composition of a typical SDS-PAGE experiment [16].

Proteins are first prepared for SDS-PAGE by denaturation using SDS, dithiothreitol (DTT)
and heat. SDS denatures both the secondary and non-disulfide-linked tertiary structures, while
DTT is a powerful reducing agent that breaks disulfide bonds [17]. Proteins must be denatured in
order to ensure movement based on molecular mass and not on protein dimension. During this
process, all proteins are turned into “rods” with a diameter of roughly one amino acid so that only
their lengths determine how quickly they pass through the gel. In addition to denaturing the protein,
SDS gives proteins a uniform net negative charge which is essential for unidirectional movement
through the polyacrylamide gel. SDS binds amino acids with a general ratio of one SDS molecule
to two amino acids. This “mass-to-charge” ratio is roughly the same for all molecules and allows
electrical force to be applied to all molecules in a relative way.
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The gel plate is comprised of polyacrylamide gel thinly sandwiched between glass or
plastic plates. The gel is made up of two parts called the “stacking gel” and “running gel” (Figure
2-4, right). The stacking gel is located at the upper portion of the gel and contains the sample wells.
It is comprised of a lower concentration of polyacrylamide to produce a large pore size mixed with
Tris-HCl buffer that has a lower pH (pH=6.8) than both the Tris-glycine running buffer (pH=8.3)
and the running gel (pH=8.8) (Figure 2-4, left) This difference in pH is essential in producing a
thin, uniform band of protein that is required for the running gel.
When a charge is applied to the system, negatively charged glycine ions in the running
buffer are forced into the stacking gel and encounter its lower pH environment. At pH=6.8, glycine
is a zwitterionic molecule (neutrally charged) which results in very slow mobility through the
stacking gel. The stacking gel also contains chloride ions (from the Tris-HCl) which are negatively
charged and run much faster through the gel than the neutral glycine. As the chloride ions move
towards the anode, an area of positive counter ions is created which results in a large voltage
gradient between the chloride ions and glycine. All of the proteins are within this gradient and are
“stacked” based on their electrophoretic mobility into thin layers at the boundary between the
stacking gel and running gel [18].
The running gel starts at the bottom of the stacking gel and continues to the bottom of the
gel plate. It contains a higher concentration of polyacrylamide to produce a smaller pore size and
has a higher pH than that of the stacking gel. Upon reaching the running gel, the stacked protein
sample encounters the dramatic change in pore size and pH. The increase in pH (to pH=8.8) results
in glycine returning to a negative charge and moving much faster, leaving the sample protein to
make its way through the gel alone. The smaller pore size causes the proteins in the sample to
separate based on their mass to charge ratio [19].
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Figure 2-5. Mechanics of the stacking gel and loading gel. The stacking gel (A) is located above the running gel and
has a pH of 6.8. At this pH, glycine molecules contain no net charge and move much more slowly than the
chloride ions, creating a voltage gradient. Proteins (red lines) in this gel are pulled along behind the fast
moving chloride ions and “stacked” at the boundary between the stacking gel and running gel. The running
gel has a pH of 8.8 which causes the glycine to have a negative charge and results in both glycine and the
chloride ions leaving the protein to move on its own. In this gel, the speed of the protein is inversely related
to its size, with small proteins moving faster than large proteins [18].

Ultimately, SDS-PAGE separates the different proteins within a sample by molecular
weight, and in combination with various staining methods, allows for detection of these molecules
(Figure 2-6). This technique is commonly used to assess the results of each step in a purification
process. SDS-PAGE analysis can identify the enrichment or loss of a target protein, allowing for
optimization and troubleshooting of the method. Finally, the purity and yield of a final protein
sample can be visually assessed.
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Figure 2-6. SDS-PAGE gel comprised of different samples taken during the purification of
NaAtm1. Samples are more fully described in Section 2.3.6.

2.2

Specialized instruments
This section will focus on two specialized instruments used during the purification process:

a fast protein liquid chromatography (FPLC) instrument and a microvolume spectrophotometer.
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2.2.1 Fast Protein Liquid Chromatography (FPLC) instrument
The FPLC instrument is essential
for purifying proteins. The AKTA Pure
(GE Healthcare) employed in this study
has

several

features

including

two

independent pumps, a column valve, an
injector port, and a fractionator for
collecting samples. It records system
pressure,

pre-column

pressure,

delta

Figure 2‐7. ÄKTA Pure FPLC made by
General Electric [20].

column pressure, absorbance at 280 nm,

and conductivity. The specific commercially available columns used in this work are as follows:

1. Ni-NTA HisTrap column:
HisTrap columns contain Ni-NTA resin (as described in the IMAC section above) and are
used to purify His-tagged proteins. The columns utilized here were either 1 mL or 5 mL in
volume, with a reported capacity of approximately 40 mg His-tagged per mL of resin.

2. HiPrep 26/10 Desalting:
This column is used for group separation of proteins from much smaller molecules. It is
most commonly used for buffer exchange after a particular chromatographic step. The
“HiPrep” name reflects the nature of its use; the maximum sample volume of 10 mL allows
for buffer exchange of larger scale protein preparations.

3. HiLoad 16/600 Superdex 200 pg
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This size exclusion column is ideal for protein separation in the 10,000 - 600,000 Da range.
It has the ability to handle up to 5mL of sample per run and is commonly used as a
secondary purification method in large scale preparations, employed to remove
contaminants of significantly differing size from that of the protein of interest.

4.

Superdex 200 Increase 10/300 GL:
This size exclusion column is ideal for protein separation in the 10,000 - 600,000 Da range
however its maximum sample volume is much smaller, only 0.5 mL and thus is used for
smaller scale preparations.

2.2.2 Spectrophotometer
A microvolume spectrophotometer was
used to determine the concentrations of all purified
proteins by measuring the proteins absorbance at
280 nm. An accurate concentration can be obtained
by using the proteins extinction coefficient (a
number derived using the total amount of amino

Figure 2-8. ImplenTM N50
Nanophotometer [21].

acids that absorb at 280 nm found within the target
protein). The nanophotometer is used because It can accurately measure absorption using 2uL of
protein, allowing for the conservation of the small amount of final purified protein that is produced
during one purification run (around 1 mL total).
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2.3 Purification of NaAtm1
2.3.1 NaAtm1 purification overview
To isolate the ABC exporter NaAtm1 for
biochemical studies, an over-expression and
purification method was employed based on a
previously published procedure [23]. This
protocol was modified as detailed below to yield
higher purity and increased yield. Using this
optimized protocol, ~10 mg of purified NaAtm1
per 30 g of cells was routinely obtained.
Figure 2-9. Structure of NaAtm1 [22].

2.3.2 NaAtm1 protein expression
The DNA plasmid containing full-length NaAtm1 was a gift of Douglas Rees (California
Institute of Technology). The gene was encoded in a pJL-H6 ligation-independent cloning vector,
which added a 6x histidine tag on the carboxy terminus of the protein. The plasmid was
transformed into BL21-Gold (DE3) E. coli (Aglient) using standard heat shock procedures.
Transformed E. coli were selected for on agar plates containing 100 µg/mL ampicillin. Single
colonies were then used to inoculate 5 mL of LB media containing 100 µg/mL ampicillin. Cultures
were incubated at 37 °C while shaking at 225 rpm for six hours. After six hours, each culture was
transferred to a Fernbach flask containing 900 mL of ZYM-5052 auto-induction media (1% (w/v)
tryptone, 0.5% (w/v) yeast extract, 0.4% (v/v) glycerol, 0.2% (w/v) lactose, and 0.05% (w/v)
dextrose), 100 mL of 10x phosphate buffer (0.17 M KH2PO4, 0.72 M K2HPO4), and 100 µg/mL
ampicillin. Four Fernbach flasks were incubated at 37 °C while being shaken at 180 rpm overnight.
The next morning the cell cultures were centrifuged at 18,370 xg for 20 minutes to pellet the cells.
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Approximately 30 g of cells were routinely obtained from 4 L of culture. Harvested cells were
either immediately used in the purification process or flash frozen using liquid nitrogen and stored
at -80 °C until needed.

2.3.3 NaAtm1 protein purification
NaAtm1 was purified using an ÄTKA Pure FPLC System (GE Healthcare) via
immobilized metal affinity chromatography followed by size exclusion chromatography. All
samples, lysates, and eluents were kept on ice or at 4 °C unless otherwise noted. 30 g of cells were
homogenized in 300 mL of NaAtm1 buffer (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 0.05%
n-Dodecyl β-D-maltoside (DDM, Anatrace)). 10 mg Deoxyribonuclease I (Sigma), 10 mg
lysozyme (Sigma), 1.5 mL of 200 mM PMSF, and 3 g of DDM (1% w/v) were added to the cells
and was stirred for 20 minutes. The suspension was sonicated on ice using a flat tip sonicator with
20% bursts of 50 kHz for 45 seconds followed by 30 seconds of cooling for 7 cycles for a total of
5.25 minutes of sonication. The lysate was then centrifuged at 28,300 xg for 20 minutes. The
clarified supernatant was collected and 4 M imidazole (pH 8) was added to a final concentration
of 25 mM. The lysate was then injected onto a 5 mL Ni-NTA HisTrap HP column (GE Healthcare)
and washed with 75 mL of NaAtm1 buffer containing 35 mM imidazole. The column was eluted
with 20 mL of NaAtm1 buffer containing a final concentration of 350 mM imidazole. Peak
fractions were collected and loaded onto a HiPrep 26/10 Desalting column (GE Healthcare)
equilibrated in NaAtm1 buffer to remove imidazole. Peak fractions were collected, pooled
(typically 10-12 mL total) and frozen in liquid nitrogen and stored at -80 ˚C. The next day, the
eluate was thawed, filtered with a 0.2 µm filter, and concentrated to 5 mL using an Amicon Ultra15 centricon with a 100,000 kD molecular weight cutoff (Millipore) and injected onto a Superdex
200 pg 16/600 sizing column (GE Healthcare). Peak fractions (eluting at approximately 60 mL
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elution volume) were collected, pooled, and concentrated as before until the final protein
concentration was approximately 15 mg/mL (extinction coefficient 152,640 M-1cm-1). Final
protein was flash frozen in liquid nitrogen and stored at -80 °C until needed.

2.3.4 NaAtm1 IMAC purification results
Immobilized metal affinity chromatography purification was carried out using both the
High Performance (HP) and Fast Flow (FF) versions of the 5 mL HisTrap (Ni-NTA) columns
produced by GE Healthcare. Results from these purifications showed that the HP HisTrap was
able to capture roughly twice the amount of NaAtm1 as the FF HisTrap (Figure 2-10). NaAtm1
purification consisted of four phases: loading, washing, eluting and desalting. During this
purification process, imidazole is used to prevent non-specific binding during loading, remove
contaminants during washing, and elute the target protein during elution. During the loading
phase, 4 M imidazole was added to roughly 300 mL of clarified supernatant containing NaAtm1,
bringing the total imidazole concentration to 25 mM. The supernatant was flowed over a HisTrap
column. This phase always produced a steady UV reading of around 2300 mAU, representing the
abundance of proteins in the cellular lysate. Once the loading phase was complete, a washing phase
using 35 mM imidazole and lasting 15 column volumes (CV) took place. This phase resulted in a
rapid decline in the UV reading from ~2300 mAU down to roughly 20 mAU. This decrease
indicates that the vast majority of non-specific-bound protein had been removed from the column
and suggests that only NaAtm1 is left bound to the column. Once washed, the protein was removed
from the column during the elution phase using 350 mM imidazole. This phase produced a sharp
peak of between 600 mAU and 2000 mAU followed by a steady UV reading of about 100 mAU
due to the high imidazole concentration (Figure 2-10).
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HisTrap FF vs. HP
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Figure 2-10. Comparison of the elution peaks for WT NaAtm1 using 5 mL HisTrap FF (blue) and 5 mL HisTrap HP
(orange) Ni-NTA columns. The HisTrap HP consistently produced elution peaks more than twice as large
as the HisTrap FF given the same amount of starting material.

The elution peak was immediately flowed over a HiPrep 26/10 Desalting column to
separate NaAtm1 from the imidazole used to elute the protein from the HisTrap column. Imidazole
needs to be removed immediately as it can interfere with enzyme activity and may destabilize the
protein. This process always produced a bell-curve shape starting around 10 mL and ending around
20 mL (Figure 2-11).
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Figure 2-11. Imidazole separation from NaAtm1 using a Size exclusion “Desalting” column. This
chromatogram shows only the peak of NaAtm1.

2.3.5 NaAtm1 SEC purification results
Following elution from the desalting column, a secondary purification process using size
exclusion chromatography was performed. This process uses a 120 mL HiLoad 16/600 Superdex
200 pg size exclusion column to remove both impurities and aggregates of NaAtm1.
Chromatograms for this process usually display two peaks at 50 mL and 64 mL (Figure 2-12). The
50 mL peak, representing the void volume of the column, contained aggregated NaAtm1 (data not
shown), while the 64 mL peak is consistent with the size of monodisperse NaAtm1 homodimers.
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Figure 2-12. Size exclusion chromatogram of secondary purification of wild-type NaAtm1.

2.3.6 Analysis of NaAtm1
Samples were collected throughout the purification process and analyzed using SDSPAGE. As seen in samples of the lysate, pellet, and supernatant, NaAtm1 was successfully
overexpressed in cells (Figure 2-13, red arrow); however, as NaAtm1 is a membrane protein, the
majority of expressed protein remained in the pellet, despite the presence of high concentrations
of detergent (Figure 2-13, green arrow). The decrease of the NaAtm1 in the flow through indicated
that majority of NaAtm1 selectively bound to the Ni-NTA resin, and the wash sample contained
mostly non-specific proteins. While the eluate for Ni-NTA and desalt columns contained multiple
proteins, the NaAtm1 band was considerably enriched relative to all other bands. Finally, the
elution sample taken following SEC showed the final purified product with minimal
contamination.
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Lane
1
2
3

Name
Ladder
Lysate
Pellet

4
5
6
7
8
9

Supernatant
Flow Through
Wash
Fractions
Desalt
Final (1 µL)

10

Final (1 µg)

Description
Molecular weight ladder (Bio-rad)
Cellular lysate post-sonification.
Insoluble cellular components, taken immediately after centrifugation
of cell lysate.
Soluble proteins, taken immediately after centrifugation of cell lysate.
Proteins that did not bind to HisTrap column
Low imidazole wash of His-Trap column
Pooled peak fractions from high imidazole elution
Pooled peak fractions from desalting column
1 µL of the pooled and concentrated fractions from size exclusion
column
1 µg of the pooled and concentrated fractions from size exclusion
column

Figure 2-13. SDS-PAGE analysis of NaAtm1.
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2.4 Purification of MSP1D1
MSP1D1 is an accessory protein
used in the assembly of nanodiscs, a
lipidic environment developed for the
study of integral membrane proteins
(Figure 2-14, orange and yellow). A full
description of its history, structure, and
implementation can be found in Chapter
3: Creating a Realistic Environment In
Vitro.

Figure 2-14. Structure of an empty Nano-disc
containing two MSP1D1 proteins
(yellow and orange) surrounding a lipid
bilayer (gray) [24].

2.4.1 MSP1D1 purification overview
The Sligar Group at the University of Illinois Urbana Champaign originally cloned
MSP1D1 and developed methods for over-expression and purification. This protocol, however, is
extremely reagent and labor intensive (requiring seven different buffers), and thus an alternative
method was developed, as described here. This new MSP1D1 purification strategy was based on
NaAtm1, and showed similar yield and purity as the Sligar method. Using this more efficient and
streamlined protocol, ~50 mg of purified MSP1D1 per 15 g of cells was routinely obtained.

2.4.2 MSP1D1 protein expression
The DNA plasmid containing full-length MSP1D1 was a gift of Douglas Rees (California
Institute of Technology). The gene was encoded in a pJL-H6 ligation-independent cloning vector
which added a 6x histidine tag on the carboxy-terminus of the protein. The plasmid was
transformed into BL21-Gold (DE3) E. coli (Aglient) using standard heat shock procedures.
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Transformed E. coli were selected for on agar plates containing 50 µg/mL kanamycin. Single
colonies were then used to inoculate 5 mL of LB media containing 50 µg/mL kanamycin. Cultures
were incubated at 37 °C while shaking at 225 rpm overnight. The next morning, each culture was
transferred to a fernbach flask containing 900 mL of Terrific Broth (TB) media (2.0% (w/v)
tryptone, 2.4% (w/v) yeast extract, and 0.4% (v/v) glycerol), 100 mL of 10x phosphate buffer
(0.017 M KH2PO4, 0.072 M K2HPO4), and 50 µg/mL kanamycin. Four Fernbach flasks were
incubated at 37 °C while being shaken at 180 rpm until the optical density of all flasks were ~0.5.
Once all flasks reached ~0.5 OD, the lactose analog IPTG was added to a final concentration of 1
mM to induce protein overexpression. The cultures were grown for an additional three hours
before being harvested via centrifugation at 18,370 xg for 20 minutes. Approximately 15 g of cells
were routinely obtained from 4 L of culture. Harvested cells were either immediately used in the
purification process or flash frozen using liquid nitrogen and stored at -80 °C until needed.

2.4.3 MSP1D1 protein purification
MSP1D1 was purified using an ÄTKA Pure FPLC System (GE Healthcare) via
immobilized metal affinity chromatography followed by size exclusion chromatography. All
samples, lysates, and eluents were kept on ice or at 4 °C unless otherwise noted. ~15 g of cells
were homogenized in 150 mL of MSP1D1 buffer (40 mM Tris-HCl, pH 7.5 and 300 mM NaCl).
10 mg Deoxyribonuclease I (Sigma), 10 mg lysozyme (Sigma), and 1.5 mL of 200 mM PMSF
were added to the cells and was stirred for 10 minutes. The suspension was sonicated on ice using
a flat tip sonicator with 20% bursts of 50 kHz for 45 seconds followed by 30 seconds of cooling
for 7 cycles for a total of 5.25 minutes of sonication. The lysate was then centrifuged at 28,300 xg
for 20 minutes. The clarified supernatant was collected and 4 M imidazole (pH 8) was added to a
final concentration of 20 mM. The lysate was then injected onto a 5 mL Ni-NTA HisTrap HP
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column (GE Healthcare) and washed with 75 mL of MSP1D1 buffer containing 35 mM imidazole.
The column was eluted with 20 mL of MSP1D1 buffer containing a final concentration of 350 mM
imidazole. Peak fractions were collected and loaded onto a HiPrep 26/10 Desalting column (GE
Healthcare) equilibrated in MSP1D1 buffer to remove imidazole. Peak fractions were collected,
pooled (typically 10-12 mL total) and frozen in liquid nitrogen and stored at -80 ˚C. The next day,
the eluate was thawed, filtered with a 0.2 µm filter, and concentrated to 5 mL using an Amicon
Ultra-15 centricon with a 10,000 kD molecular weight cutoff (Millipore) and injected onto a
Superdex 200 pg 16/600 sizing column (GE Healthcare). Peak fractions (eluting at approximately
75 mL elution volume) were collected, pooled, and concentrated as before until the final protein
concentration was approximately 15 mg/mL (extinction coefficient 21,430 M-1cm-1). Final
protein was flash frozen in liquid nitrogen and stored at -80 °C until needed.

2.4.4 MSP1D1 IMAC purification results
Immobilized metal affinity chromatography purification was carried out using a High
Performance (HP) 5 mL HisTrap (Ni-NTA) columns produced by GE Healthcare. MSP1D1
purification consisted of four phases: loading, washing, eluting and desalting. The resulting
profiles are similar to those seen in the NaAtm1 purification procedure. During the loading phase,
roughly 150 mL of clarified supernatant containing overexpressed MSP1D1 was flowed over a
HisTrap column. This phase always produced a steady UV reading of around 2600 mAU,
representing the abundance of proteins in the cellular lysate. Once the loading phase was complete,
a washing phase lasting 15 column volumes (CV) took place. This phase resulted in a rapid decline
in the UV reading from ~2600 mAU down to roughly 20 mAU. This step was necessary to remove
any non-specific proteins bound to the column. Once washed, the protein was removed from the
column during the elution phase. This phase produced a peak of around 2000 mAU followed by a
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UV reading of about 100 mAU due to the high imidazole concentration (Figure 2-15). The height
of the absorbance peak indicated a high concentration of protein was present in the eluate.
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Figure 2-15. Primary purification of MSP1D1 using a 5 mL HisTrap HP column.

Once eluted, the peak fractions were immediately flowed over a HiPrep 26/10 Desalting
column to separate MSP1D1 from the high concentration of imidazole used in Ni-NTA elution.
This process always produced a bell-curve shape starting around 10 mL and ending around 25 mL
(Figure 2-16).
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Figure 2-16. Imidazole separation from MSP1D1 using a size exclusion-type “desalting” column.

2.4.5 MSP1D1 SEC purification results
Following elution from the desalting column, a secondary purification process using size
exclusion chromatography was performed. This process employed a 120 mL HiLoad 16/600
Superdex 200 pg size exclusion column to remove any remaining impurities and aggregates of
MSP1D1. Chromatograms for this process routinely displayed two peaks at 50 mL and 75 mL
(Figure 2-17). The protein eluting at the 50 mL void volume was comprised of aggregated
MSP1D1 (data not shown), while the peak at 75 ml consisted of purified MSP1D1. A faint shoulder
was normally seen after the main peak eluted. These fractions were not collected and not part of
the purified MSP1D1.
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Figure 2-17. Size exclusion chromatogram of secondary purification of MSP1D1

2.4.6 Analysis of MSP1D1
Samples were collected throughout the purification process and analyzed using SDSPAGE. The purification of MSP1D1 can be followed using these samples (Figure 2-18, red arrow).
The absence of the MSP1D1 in the flow through indicated that MSP1D1 selectively bound to the
Ni-NTA resin, and the wash sample contained only non-specific proteins. While the eluate for NiNTA and desalt columns contained multiple proteins, the MSP1D1 band was considerably
enriched relative to all other bands. Finally, the elution sample taken following SEC showed the
final purified product with minimal contamination.
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Name
Ladder
Lysate
Pellet

4

Supernatant

5
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7
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Flow Through
Wash
Fractions
Desalt
Final (1 µL)

10

Final (1 µg)

Description
Molecular weight ladder (Bio-rad)
Cellular lysate post-sonification.
Insoluble cellular components, taken immediately after
centrifugation of cell lysate.
Soluble proteins, taken immediately after centrifugation of cell
lysate.
Proteins that did not bind to HisTrap column
Low imidazole wash of His-Trap column
Pooled peak fractions from high imidazole elution
Pooled peak fractions from desalting column
1 µL of the pooled and concentrated fractions from size exclusion
column
1 µg of the pooled and concentrated fractions from size exclusion
column

Figure 2-18. SDS-PAGE of MSP1D1
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2.5 Purification of TEV protease
TEV Protease is a highly specific protease that
is used to remove engineered His-tags from proteins
produced in a heterologous expression system. This
protein and its application are described in detail in
Chapter 3: Creating a Realistic Environment in Vitro.

2.5.1 TEV protease purification overview

Figure 2-19. Cartoon model of
TEV protease [25].

The TEV protease purification strategy follows a procedure developed by the Narlikar
Group at the University of California, San Francisco. Using a modified version of this protocol,
~10 mg of purified TEV protease per 15 g of cells was obtained.

2.5.2 TEV protease protein expression
The DNA plasmid containing full-length S219V mutant TEV protease was a gift from
Geeta Narlikar. The gene was encoded in a pMal-C2 ligation-independent cloning vector which
added a 6x histidine tag on the carboxy terminus of the protein. The plasmid was transformed into
BL21-Gold (DE3) E. coli (Aglient) using standard heat shock procedures. Transformed E. coli
were selected for on agar plates containing 100 µg/mL ampicillin. Single colonies were then used
to inoculate 5 mL of LB media containing 100 µg/mL ampicillin. Cultures were incubated at 37
°C while shaking at 225 rpm overnight. The next morning, each culture was transferred to a
Fernbach flask containing 1 L of 2x Luria Broth (LB) media (2% (w/v) tryptone, 1% (w/v) yeast
extract, and 2% (v/v) NaCl) and 100 µg/mL ampicillin. Four Fernbach flasks were incubated at 37
°C while being shaken at 180 rpm until the optical density of all flasks were ~0.5. Once all flasks
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reached ~0.5 OD, the lactose analog IPTG was added to a final concentration of 0.4 mM to induce
protein production. The flasks were then incubated at 18 °C while shaking at 180 rpm overnight.
The next morning, the cell cultures were centrifuged at 18,730 xg for 20 minutes to pellet the cells.
Approximately 15 g of cells were obtained from 4 L of culture. Harvested cells were either
immediately used in the purification process or flash frozen using liquid nitrogen and stored at 80 °C until needed.

2.5.3 TEV protease protein purification
TEV protease was purified using an ÄTKA Pure FPLC System (GE Healthcare) via
immobilized metal affinity chromatography followed by size exclusion chromatography. All
samples, lysates, and eluents were kept on ice or at 4 °C unless otherwise noted. ~15 g of cells
were homogenized in 150 mL of TEV protease lysis buffer (1x PBS, 300 mM KCl, 10% glycerol,
and 7.5 mM Imidazole pH 7.5). 10 mg Deoxyribonuclease I (Sigma) and 10 mg lysozyme (Sigma)
were added to the cells and was stirred for 10 minutes. The suspension was sonicated on ice using
a flat tip sonicator with 20% bursts of 50 kHz for 45 seconds followed by 30 seconds of cooling
for 7 cycles for a total of 5.25 minutes of sonication. The lysate was then centrifuged at 28,300 xg
for 20 minutes. The clarified supernatant was collected and 4 M imidazole (pH 8) was added to a
final concentration of 20 mM. The lysate was then injected onto a 5 mL Ni-NTA HisTrap HP
column (GE Healthcare) and washed with 75 mL of TEV protease lysis buffer containing 35 mM
imidazole. The column was eluted with 20 mL of TEV protease elution buffer (25 mM HEPES,
100 mM KCl, 10% glycerol, and 500 mM Imidazole pH 7.5) containing a final concentration of
350 mM imidazole. Peak fractions were collected and loaded onto a HiPrep 26/10 Desalting
column (GE Healthcare) equilibrated in TEV protease storage buffer (25 mM HEPES, 300 mM
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KCl, 10% glycerol, and 2 mM DTT pH 7.5) to remove imidazole. Peak fractions were collected,
pooled (typically 10-12 mL total), frozen in liquid nitrogen and stored at -80 ˚C. The next day, the
eluate was thawed, filtered with a 0.2 µm filter, and concentrated to 5 mL using an Amicon Ultra15 centricon with a 10,000 kD molecular weight cutoff (Millipore) and injected onto a Superdex
200 pg 16/600 sizing column (GE Healthcare). Peak fractions (eluting at approximately 75 mL
elution volume) were collected, pooled, and concentrated as before until the final protein
concentration was approximately 15 mg/mL (extinction coefficient 36,130 M-1cm-1). Final
protein was flash frozen in liquid nitrogen and stored at -80 °C until needed.

2.5.4 TEV protease IMAC purification results
Immobilized metal affinity chromatography purification was carried out using a High
Performance (HP) 5 mL HisTrap (Ni-NTA) columns produced by GE Healthcare. TEV protease
purification consisted of four phases: loading, washing, eluting and desalting. During the loading
phase, roughly 150 mL of clarified supernatant containing TEV protease was flowed over a
HisTrap column. This phase produced a steady UV reading of around 2500 mAU. Once the loading
phase was complete, a washing phase lasting 15 column volumes (CV) took place. This phase
resulted in a rapid decline in the UV reading down to roughly 20 mAU. After washing, the TEV
protein was removed from the column during the elution phase. This phase produced a broad peak
of around 900 mAU.

79

3000

Absorbance 280nm (mAU)

2500
2000
1500
1000
500
0
0

50

100

150

200

250

Volume (mL)
Figure 2-20. Primary purification of TEV using a 5 mL HisTrap HP column.

Once eluted, the fractions containing the elution peak were immediately flowed over a
HiPrep 26/10Desalting column to remove imidazole from the TEV protease This process always
produced a bell-curve shape starting around 10 mL and ending around 25 mL (Figure 2-21).
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Figure 2-21. Imidazole separation from TEV protease using a Size exclusion “Desalting” column.
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2.5.5 TEV protease SEC purification results
Following elution from the desalting column, a secondary purification process using size
exclusion chromatography was performed. This process uses a 120 mL HiLoad 16/600 Superdex
200 pg size exclusion column to remove both impurities and aggregates of TEV protease. The
chromatogram for this process displayed multiple peaks with the largest eluting at 90 mL (Figure
2-22). For this purification, only the largest peak was evaluated; no analysis was done on the
smaller peaks.
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Figure 2-22. Size exclusion chromatogram of secondary purification of TEV protease.

2.5.6 Analysis of TEV Protease
Samples were collected throughout the purification process and analyzed using SDSPAGE. As seen in samples of the lysate, pellet, and supernatant, TEV protease was successfully
overexpressed in cells (Figure 2-23, red arrow). The absence of the TEV protease in the flow
through indicated that TEV protease selectively bound to the Ni-NTA resin, and the wash sample
contained only non-specific proteins. While the eluate for Ni-NTA and desalt columns contained
multiple proteins, the TEV protease band was considerably enriched relative to all other bands.
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Finally, the elution sample taken following SEC showed the final purified product with minimal
contamination.

Lane
1
2
3

Name
Ladder
Lysate
Pellet

4
5
6
7
8
9

Supernatant
Flow Through
Wash
Fractions
Desalt
Final (1 µL)

10

Final (1 µg)

Description
Molecular weight ladder (Bio-rad)
Cellular lysate post-sonification.
Insoluble cellular components, taken immediately after centrifugation
of cell lysate.
Soluble proteins, taken immediately after centrifugation of cell lysate.
Proteins that did not bind to HisTrap column
Low imidazole wash of His-Trap column
Pooled peak fractions from high imidazole elution
Pooled peak fractions from desalting column
1 µL of the pooled and concentrated fractions from size exclusion
column
1 µg of the pooled and concentrated fractions from size exclusion
column

Figure 2-23. SDS-PAGE analysis of a TEV protease purification.
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2.6 Conclusion
This chapter highlights some of the indispensable tools used in protein purification, which
is the essential first step in most biochemical studies. Immobilized metal affinity chromatography
(IMAC) and size exclusion chromatography (SEC), in combination with sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE), were used in the purification of three different
proteins overexpressed in E.coli: NaAtm1, MSP1D1, and TEV protease. Using experimental
conditions optimized for each protein, all three were successfully obtained with high purity and
yield. With these components in-hand, the next step was to utilize MSP1D1 and TEV protease to
create a realistic environment to study NaAtm1, as described in Chapter 3.
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CHAPTER 3
Creating a Realistic Environment in Vitro

3.1

Introduction
In order to accurately dissect the mechanism of any protein of interest, experiments must

be performed under conditions that mimic the native environment as closely as possible. In order
to understand how NaAtm1 drives transport in a membrane, we aimed to incorporate NaAtm1 into
a robust and reliable lipid bilayer system.
I have always thought of ABC transporters as the doorways of the cell. Indeed, they are
devices that allow selective passage through a lipid bilayer (wall), they have mechanisms (NBDs)
that require energy to physically change their 3D structure (door handles), and they have conserved
amino acid sequences that allow these conformational changes to take place (hinges).
Unfortunately, as with most doors, when they are removed from their wall they no longer act as
doors. If one wanted to study how these doors opened and closed, it would be advantageous to
make a temporary frame, wall, or room to put them in. There are three common environments used
to mimic a lipid bilayer: detergent micelles, liposomes, and nanodiscs.
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Figure 3-1. Analogies to the different environments created for membrane protein experiments A) A bare membrane
protein: without a supporting structure the protein will not function – like a door without a frame. B) A
membrane protein surrounded by a detergent micelle: a minimum supporting structure that allows the
protein to function – like a flimsy door frame around a door. C) A protein surrounded by a liposome: a full
replica of a cell – like building an entire room for a door (more effort than necessary). D) A membrane
protein surrounded by a nanodisc: acts as a wall that can give the door proper structure to function while
keeping the structure simple and robust.

3.2

Types of Environments
To maintain its inclusion within a lipid bilayer, integral membrane proteins, including ABC

transporters, have many hydrophobic residues lining the exterior surface of the transmembrane
domains. If a transporter is removed from the lipid bilayer and placed into an aqueous environment,
these hydrophobic residues will rearrange to fold in on themselves or will drive the aggregation of
multiple protein molecules. To maintain the structure of transporters after extraction from the
native cell membrane, scientists have developed several lipid bilayer-like environments.
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3.2.1 Detergent micelles
A detergent micelle is a self-assembling collection of surfactants –
amphipathic molecules that contain a hydrophilic polar head group and a
hydrophobic non-polar tail. When a critical concentration of these
Figure 3-2. Structure
of a Micelle [1].

molecules is reached, they assemble in an organized way that creates a

sphere of polar head groups with the non-polar tails on the interior of this sphere (Figure 3-2).
If present above the critical micelle concentration, detergents can cover the hydrophobic
portions of a transporter to prevent deformation and aggregation. While this alleviates some of the
issues involved with isolating a membrane protein in aqueous solution, it does have limitations.
The architecture of the surrounding micelle is fundamentally different from a bilayer, introducing
artificial contacts between the hydrophobic surfaces of the protein and its environment. These
interactions could alter native structure and dynamics of the transporter and therefore change its
activity.
Additionally, the micelle environment does not allow for the ability to directly monitor the
movement of substrate across a membrane. Given the lack of a discrete compartment in which
substrate can accumulate, experiments to measure transporter activity are limited to indirect
strategies, such as the stimulation of ATPase activity or detection of conformational change within
the protein.
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3.2.2 Liposomes
Liposomes are artificially created vesicles – spheres composed of
a closed phospholipid bilayer (Figure 3-3). Phospholipids are similar to
detergents in that they have a polar head and a hydrophobic tail
Figure 3-3. Structure
of a liposome [1].

component, however their chemical structure is very different. One major
difference is that detergents only have one hydrophobic tail while

phospholipids have two (Figure 3-4). The ultimate effect of the two lipid tails is the formation of
a lipid bilayer, and if there is enough bilayer, it is thermodynamically favored to close upon itself
when in aqueous solution. There are both advantages and disadvantages to using liposomes over
micelles. One major advantage is that liposomes have a true phospholipid bilayer that more closely
resembles the natural membrane environment. Another advantage is that due to the closed nature
of the environment (presence of the internal cavity), transporters that are placed in a liposome can
be evaluated for substrate transport.

Figure 3-4. Structures of the phospholipid phosphatidylcholine (PC) and the detergent sodium dodecyl sulfate (SDS).
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Figure 3-5. Liposome containing a 1:1 ratio of inward and outward facing ABC transporters. In this scenario the ABC
transporters are importers.

Unfortunately, creating and maintaining liposomes can be very challenging due to their
size. A major experimental challenge in using ABC transporters in a liposome is its orientation
within the membrane. While many scientists assume an equal distribution (50% outward, 50%
inward, Figure 3-5), the specific activity of the transporter is difficult to accurately measure.
Furthermore, the insertion of membrane proteins into a liposome is demanding in practice – large
amounts of protein must be available for reconstitution procedures which may require multiple
rounds of optimization given a particular transporter.

3.2.3 Nanodiscs
Nanodiscs are small sections of phospholipid bilayer held together by an alpha-helical
protein belt. This belt is a genetically modified form of human apolipoprotein A1 (Figure 32a).
Apolipoprotein A1 is a major protein component of HDL particles found in plasma and plays a
major role in lipid transport throughout the body [2]. It is comprised of a globular region followed
by multiple amphipathic α-helices (Figure 3-6B). Nanodiscs were first reported by Baybert et al.
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in 1998 [3], with the modified apolipoprotein described as a “Membrane Scaffold Protein” (MSP).
All MSPs have been modified by replacing the globular region with a histidine tag and TEV
protease cleavage site, and each contain varying numbers of α-helices. By varying the number of
α-helices contained in the MSP, the final disc diameter can be modulated to accommodate different
sizes of transmembrane proteins. Membrane scaffold proteins are now widely available in
diameters ranging from 7 to 17 nm.

Figure 3-6. A) Structure of a nanodisc containing a transmembrane protein (green), surrounded by a phospholipid
bilayer (red spheres with gray tails), held together by two modified Apolipoproteins (MSPs) (purple). B)
Organization of the naturally occurring Apolipoprotein A1 and two genetically modified MSPs, MSP1D1
and MSP1E3D1 [4].

In contrast to liposomes, nanodiscs are relatively easy to generate in a self-assembling
process. As with the detergent micelle, this system is open, which makes it impossible to determine
if a substrate is being transported through the protein or if it is merely stimulating activity. Even
with this drawback, they are less labor intensive and more durable than liposomes while creating
a more realistic environment than detergent micelles. While detergent micelles stabilize isolated
membrane proteins in an aqueous solution and are relatively easy to create, there have been
discrepancies in enzyme activity based on the choice of mimetic environment in general. For
example, BtuCD transporters reconstituted into nanodiscs have been shown to have an almost 6fold decrease in uncoupled hydrolysis compared to transporters in detergent micelles [5]. It is
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believed that these discrepancies come from the detergents causing the protein to adopt a structure
that is different from the one it takes in lipid. To address this issue and to create a more realistic
environment to test NaAtm1, we aimed to insert NaAtm1 into nanodiscs as described below.

3.3

Overview of nanodisc reconstitutions
NaAtm1 nanodiscs are created in a self-assembling reaction that requires purified

Membrane Scaffold Protein (MSP), micelles containing a mixture of lipid and detergent, and
purified NaAtm1 in detergent micelles. When these components are mixed using an optimized
molar ratio of NaAtm1-MSP1D1-Lipid, small polystyrene “Bio-Beads” are added. These beads
absorb the detergent from both the purified NaAtm1 as well as the lipid/detergent micelles while
leaving the lipid component untouched. This results in the accumulation of lipid around NaAtm1
and other lipids. The MSP1D1 then wraps around the lipid to form both full discs (containing
embedded transporter) and empty discs (Figure 3-7). Finally, the full disc species is isolated via
chromatography.

Figure 3-7. Overview of the nanodisc reconstitution process [6, 7]. This process consists of combining the target
membrane protein with MSP, lipid/detergent micelles, and Bio-Beads. The Bio-Beads absorb the detergent
from the lipid/detergent micelles as well as the detergent micelles around the target membrane protein.
This process results in the accumulation of lipid around the membrane protein and other lipids resulting in
full and empty nanodisc.
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3.3.1. Preparation of nanodisc reagents
3.3.1.1 Membrane scaffold protein (MSP)
The NaAtm1 reconstitutions described here employs MSP1D1,
which was chosen due to its availability and final diameter of ~9.7 nm.
At ~9.7 nm, the lipidic area accommodates only one NaAtm1. MSP1D1
contains an N-terminal His-tag (7x histidine residues), a TEV protease

Figure 3-8: Cartoon
rendering of MSP1D1 [7].

cleavage site, and ten α-helices (Figure 3-9B). Two MSP1D1 proteins
wrap around the lipid bilayer form one disc that measures roughly 9.8 nm in diameter and 4.6 nm
(lipid bilayer only) in height. The purification of this protein can be found in Chapter 2.

Figure 3-9. A) The amino acid sequence of MSP1D1. B) Comparison of Apolipoprotein A1 and MSP1D1 [4].

3.3.1.2 1:3 PC:E lipids
The lipid mixture used in reconstitutions was based on previous studies using ABC
transporters [8]. A 1:3 ratio of chicken egg phosphatidylcholine (PC) to E. coli polar lipid extract
is a common starting point for reconstitutions. The composition of each of these components is
shown in Figure 3-10.
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Figure 3-10. A) Natural lipid mixture found in chicken egg PC. B) Composition of E. coli polar extract. C) Representative
structure of phosphatidylcholine (PC) from chicken egg [9, 10].

To prepare this lipid mixture, commercially available chloroform stocks of egg PC and E.
coli polar lipid extract were mixed with a final mass of 100 mg of chicken egg PC to 300 mg of E.
coli polar extract (Avanti Polar Lipids). Lipids were transferred to a 500 mL balloon flask and
rotovaped to remove chloroform. Once dry, the flask was wrapped in tinfoil to prevent
photodegredation, and was placed in a desiccator overnight under vacuum to remove any
remaining chloroform.
The next morning, 15 mL of Reconstitution Buffer A (20 mM Tris HCl (pH 7.5) and 100
mM NaCl) was added to the flask. The mixture was then placed under argon to prevent oxidation
and shaken overnight at room temperature at 120 rpm. The following day, the resuspended lipids
were collected, and 5 mL of Reconstitution Buffer A was added to the flask to recover any
remaining lipid. The resuspended lipids were then brought to a final concentration of 20 mg/mL
in Reconstitution Buffer A. This lipid stock was then placed on ice and sonicated using a using a
Branson Sonifier 250 with an output of 4.5 and a duty cycle of 20% for six cycles of 15 seconds
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sonification with a 45 second cool-down period in between. Once sonicated, the lipids were
divided into 100 µL aliquots, flash frozen in liquid nitrogen, and stored at -80 °C.
For use in reconstitutions, lipids were further processed on a smaller scale. Because
nanodiscs form upon removal of detergent, both from the hydrophobic region of the membrane
protein and from the lipid/detergent micelles by Bio-beads, the type of detergent used in this
process is very important. The detergent sodium cholate is used to create lipid/detergent micelles
for use in this process to due sodium cholates ability to be quickly and easily removed from the
mixture - allowing for plenty of lipid to be present for the membrane protein to surround itself with
once out of its detergent micelle. 4 mg of sodium cholate was added to 2 mg of lipid and brought
up to a 1 mL total volume using NaAtm1 Buffer A. This mixture was vortexed and then placed in
a waterbath sonicator for 30 minutes. The ultimate composition of the lipid mixture used in
reconstitutions was 2 mg/mL 1:3 (w/w) egg PC: E. coli polar lipid extract, 4 mg/mL sodium
cholate, and approximately 20 mM Tris, 100 mM NaCl, and 0% DDM.

3.3.1.3 Bio-Beads
Dry Bio-Beads (Amberlite® XAD-2) were purchased from Bio-Rad. ~15 mL of dry BioBeads were first washed with 100% methanol in a 50 mL conical tube. After inverting multiple
times, the Bio-Beads were allowed to settle before removal of the methanol. The process was
repeated using an additional round of 100% methanol, 2 rounds of 95% ethanol, 2 rounds of
ddH2O, and finally 2 rounds Reconstitution Buffer A. Washed Bio-Beads were stored in a minimal
volume of Reconstitution Buffer A (enough to prevent beads from drying out) and stored at 4 °C
until needed.
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3.3.2 Reconstitution methods
3.3.2.1 Assembly and purification of small-scale reconstitutions
As shown in published literature, each integral membrane protein requires an optimized
ratio of protein-of-interest, scaffolding protein, and lipid. To determine the proper conditions for
assembly of NaAtm1 nanodiscs, a series of small-scale reconstitutions were prepared and
analyzed.
In general, small-scale reconstitutions were approximately 300 µL in volume and prepared
in 1.5 mL microcentrifuge tubes. Reagents were added in the order of lipid, MSP1D1,
Reconstitution Buffer A (20 mM Tris-HCl and 150 mM NaCl pH 7.5), and NaAtm1. 50 µL of wet
Bio-Beads was then added, and the mixture placed on an Adams Nutator at 4 °C overnight.
The following day, the reconstitution was centrifuged for 1 minute at maximum speed in a
microcentrifuge to pellet the Bio-Beads. The supernatant was then applied to a 0.22 µm filter to
remove aggregates. The sample was injected over a Superdex 200 Increase 10/300 GL sizing
column at 1 mL/min. Elution fractions were collected for subsequent analysis.

3.4

Reconstitution results

3.4.1 Identification of multiple species present in reconstitutions
Initial reconstitutions were created using a 1-3-60 molar ratio of NaAtm1-MSP1D1-lipid
with a final transporter concentration of 10 µM, as recommended in published protocols [11]. This
reconstitution yielded three peaks (Figure 3-11) at ~12 mL, ~13.75 mL, and ~15.75 mL. A sample
of each peak was analyzed using SDS-PAGE (not shown) and it was determined that Peak 1
contained both NaAtm1 and MSP1D1 while Peaks 2 and 3 contained only MSP1D1. This result
suggested that the Peak 1 contained NaAtm1 successfully embedded in a nanodisc; however, more
testing was needed to verify the composition of this species. For this section, Peak 1 refers to the
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peak that elutes at ~12 mL elution volume, Peak 2 refers to the peak that elutes at ~13.75 mL
elution volume, and Peak 3 refers to the peak that elutes at ~15.75 mL elution volume.

Figure 3-11. 1-3-60 NaAtm1-MSP1D1-Lipid reconstitution with a final NaAtm1 concentration of 10 µM and a final
volume of 300 uL.

3.4.1.1 Reconstitution without NaAtm1: 0-3-60
To aid in identifying the multiple peaks, different versions of the 1-3-60 reconstitutions
were prepared with one component removed (i.e. 0-3-60, 1-0-60, 1-3-0) at 5 µM final transporter
concentration.
A 0-3-60 NaAtm1-MSP1D1-lipid reconstitution yielded two peaks at the same elution
volume as Peaks 2 and 3 from the 1-3-60 reconstitution, with no peak at the same elution volume
as Peak 1. A sample of each peak was analyzed using SDS-PAGE (data not shown), and it was
determined that both peaks contained only MSP1D1, as expected. This result demonstrated that
NaAtm1 was a critical component of the species in Peak 1 seen in the 1-3-60
reconstitution. Furthermore, this suggested that the Peak 1 did not contain MSP1D1 aggregates,
excess nanodisc without transporter (“empty disc”), or MSP1D1 dimers or monomers.

98

Figure 3-12. Size exclusion chromatogram of a 0-3-60 5 µM 300 µL reconstitution. This chromatogram shows two
peaks that match Peaks 2 and 3 respectively in the 1-3-60 chromatogram (Figure 3-11).

3.4.1.2 Reconstitution without MSP1D1: 1-0-60
A reconstitution with a molar ratio of 1-0-60 of NaAtm1-MSP1D1-lipid was then created.
This reconstitution yielded a peak at the void volume, which is most likely a collection of nonfunctional masses of NaAtm1 transporters. In the absence of the lipid bilayer enclosed by
MSP1D1, removal of detergent by Bio-Beads would drive aggregation of the hydrophobic regions
of NaAtm1. This result implies that MSP1D1 is a critical component of Peak 1 in the 1-3-60
reconstitution.

Figure 3-13. Size exclusion chromatogram of a 1-0-60 5 µM 300 µL reconstitution. This chromatogram shows a small
peak at the void volume for the column used. This suggests that in the absence of MSP1D1, NaAtm1
cannot remain soluble after removal of detergent
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3.4.1.3 Reconstitution without additional lipids: 1-3-0
A reconstitution with a molar ratio of 1-3-0 was then created. This reconstitution yielded
two peaks that matched Peak 1 and Peak 3 in the 1-3-60 reconstitution. This interesting result
might be due to the presence of a small amount of lipid around both NaAtm1 and MSP1D1 that
was not removed during purification. The combination of the small lipid stores around each protein
could be enough to create an intact nanodisc. These observations suggest that lipid is a critical
factor in Peak 2 but not in Peak 3. This leads to the conclusion that Peak 2 forms only in the
presence of both MSP1D1 and lipid. In addition, the 0-3-60 reconstitution showed that NaAtm1 is
not a critical component of Peak 2 or 3. Together, these findings suggest that Peak 2 is empty
nanodisc and Peak 3 is excess MSP1D1.

Figure 3-14. Size exclusion chromatogram of a 1-3-0 5 µM 300 µL reconstitution. This chromatogram shows two peaks
that correspond to Peak 1 and 3 respectively in the 1-3-60 reconstitution (Figure 3-11).
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3.4.2 Conclusion for peak identification in small-scale reconstitutions
In summary, a 1-3-60 ratio of nanodisc components resulted in three peaks resolved by size
exclusion chromatography: NaAtm1 successfully reconstituted nanodiscs (Peak 1), empty
nanodiscs (Peak 2), and excess MSP1D1 that had not formed nanodiscs (Peak 3) (Figure 3-15).

Figure 3-15. A comparison of size exclusion chromatograms of reconstitutions with and without NaAtm1.

3.4.3 Reconstitution optimization
Once the different species in the initial 1-3-60 reconstitution were identified, the reconstitution
method was optimized to maximize the yield of NaAtm1 nanodiscs. To accomplish this, three
different variables were altered: NaAtm1:MSP1D1 molar ratio, NaAtm1:Lipid molar ratio, and
final NaAtm1 concentration.

3.4.3.1 NaAtm1:MSP1D1 optimization
Five reconstitutions were created using different molar ratios of NaAtm1:MSP1D1 (1-360, 1-4-60, 1-5-60, 1-6-80, and 1-7-80 NaAtm1-MSP1D1-Lipid). Each reconstitution was
analyzed using size exclusion chromatography and overlaid for comparison (Figure 3-16). These
data showed that the height of Peak 1 significantly increased when the ratio was changed from 1:3
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to 1:4, but for higher ratios (1:5-1:7) there was no appreciable difference in Peak 1 height. It was
also observed that as the molar ratio of NaAtm1:MSP1D1 increased, both Peak 2 and Peak 3
increased as well. This suggests that at a molar ratio of 1:4, the reaction has gone to completion
and that NaAtm1 is now the limiting reagent. From this conclusion, the molar ratio 1:4
NaAtm1:MSP1D1 was chosen for future reconstitutions.

Figure 3-16. Comparison of reconstitutions created using different molar ratios of NaAtm1:MSP1D1.

3.4.3.2 NaAtm1:Lipid optimization
Four reconstitutions were created using different molar ratios of NaAtm1:Lipid (1-5-50, 15-60, 1-5-80, and 1-5-120 NaAtm1-MSP1D1-Lipid). The NaAtm1:MSP1D1 molar ratio of 1:5
was chosen instead of 1:4 to increase the prominence of Peak 3 within this experiment. By using
a ratio that produces a more noticeable Peak 3, the resulting change in the peak is visible while
changing the NaAtm1:Lipid ratio. Analysis via size exclusion chromatography showed that the
height of Peak 1 increased from 1:50 to 1:60 (data not shown) but for higher ratios (1:80, 1:120)
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there was no appreciable difference in Peak 1 height. It was also observed that as the molar ratio
of NaAtm1:lipid increased, the Peak 2 increased while Peak 3 decreased.
These data suggest that as the amount of lipid increases, the formation of nanodisc is driven
to completion, dictated by the amount of scaffolding protein. When NaAtm1 is the limiting reagent
for primary product formation (full nanodisc), the secondary product (empty nanodisc)
accumulates. This data is consistent with the initial conclusions (Section 3.4.1) that Peak 2 contains
empty nanodisc and Peak 3 contains excess MSP1D1.

For the optimization of these

reconstitutions, the goal was to maximize the NaAtm1 nanodiscs identified in Peak 1, while
minimizing the empty nanodiscs found in of Peak 2. The results suggest that these parameters are
best met with a molar ratio 1:60 NaAtm1:Lipid.

Figure 3-17. Comparison of reconstitutions created using different molar ratios of NaAtm1:Lipid.
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3.4.3.3 Final NaAtm1 concentration optimization

The last condition that was explored was the final NaAtm1 concentration of all of the
components at a fixed ratio, which was necessary for scaling up to larger amounts of nanodiscs.
Reconstitutions of 1-5-80 were prepared at 5 µM, 10 µM, 15 µM, and 20 µM NaAtm1. For
example, the 15 µM sample would consist of 15 µM NaAtm1, 75 µM MSP1D1, and 1200 µM
lipids. All reconstitutions were tested in a 300 µL and analyzed by size exclusion chromatography
(Figure 3-18).

Figure 3-18. Comparison of reconstitutions created using different final concentrations of NaAtm1.

As expected, the height of all peaks were directly correlated with final protein
concentration. With multiple repeats, however, it was observed that reconstitutions at high
concentrations were less reproducible than at lower concentrations. High concentration
reconstitutions often resulted in extremely low amounts of total recovered material (data not
shown). One explanation is that the high concentration of material would be more easily prone to
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aggregation, which would be removed by routine sample filtration before the analysis on the size
exclusion column. Due to the difficulty in reproducibility at higher final transporter concentrations,
5 µM final NaAtm1 concentration was used for subsequent reconstitutions.

3.4.4 Optimization conclusion
The results of these experiments show that an optimized reconstitution for NaAtm1 in
MSP1D1 using 1:3 PC:E lipid consists of a molar ratio of 1-4-60 with a final NaAtm1
concentration of 5 µM.

3.5

Determining the stoichiometry of nanodiscs using densitometry
Once the reconstitution ratio was optimized, the resulting purified nanodiscs were analyzed

to determine the molar ratio of NaAtm1 to MSP1D1. This was necessary for two reasons: (1) to
ensure that each nanodisc contained only one NaAtm1, and (2) to create a method for
quantification of nanodiscs via absorbance spectroscopy.
To accomplish this, nanodiscs were analyzed by SDS-PAGE and stained using the
fluorescent protein gel stain SYPRO Ruby, which is highly quantitative and sensitive to low
protein concentrations (Figure 3-19). For these densitometry experiments, a standard curve was
generated for both NaAtm1 and MSP1D1 based on the molecular weight of each (135361 g/mol
and 24793 g/mol, respectively). The protein solutions used to prepare the standard curve were
quantified using the calculated extinction coefficient of each (152,640 M-1 cm-1 and 24130 M-1
cm-1, respectively). Serial dilutions of the purified NaAtm1 nanodiscs samples were prepared
identically, with SDS and DTT present to denature and separate protein complexes. As seen in
Figure 3-19, both MSP1D1 and NaAtm1 were present in the isolated nanodiscs.
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Figure 3-19. SDS-PAGE analysis using SYPRO Ruby stain.

The intensities of the protein bands in the “NaAtm1 Standard” and “MSP1D1 Standard”
were quantified to create a standard curve for each protein (Figure 3-20). The standard curve for
NaAtm1 was then used to determine how much NaAtm1 was present in each lane of the
“Reconstitution” serial dilutions (Figure 3-19, “Reconstitution” top protein band) while the
MSP1D1 standard curve was used to determine how much MSP1D1 was present in each lane of
the “Reconstitution” serial dilutions (Figure 3-19, “Reconstitution” bottom protein band).

Figure 3-20. A) NaAtm1 standard curve with an R2 value of 0.9916. B) MSP1D1 standard curve with an R2 value of
0.9564
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The amount of each component (NaAtm1 and MSP1D1) in each lane was then compared
to determine the NaAtm1:MSP1D1 ratio (w/w). The average NaAtm1:MSP1D1 ratio (w/w) over
multiple lanes was 2.75:1 (Table 3-1). This experimentally determined w/w ratio is remarkably
similar to the ideal calculated w/w ratio of 2.73:1, which corresponds to a 1:2 mol ratio of
NaAtm1:MSP1D1. This result strongly suggests that the nanodiscs produced during this
experiment contain a molar ratio of 1:2 NaAtm1:MSP1D1.
NaAtm1 calculated using
Standards (µg):

MSP1D1 calculated using Standards (µg):

Label:
Lane 19

1.645

0.595

2.766

Lane 20

1.618

0.592

2.733

Lane 21

1.581

0.577

2.740

Lane 22

1.290

0.470

2.744

Lane 23

1.137

0.418

2.718

Lane 24

0.924

0.308

2.997

Lane 25

0.711

0.253

2.810

Lane 26

0.503

0.201

2.499

Average:

2.751

Ratios:

Table 3-1. Representative comparison of component parts quantified by densitometry

3.6

Quantification of NaAtm1 nanodiscs via absorbance spectroscopy
Based on the results of the densitometry analysis above, a simple “correction factor” could

be calculated to allow for the quantification of NaAtm1 nanodiscs via absorbance measurement at
280 nm. Using samples containing the same amount of NaAtm1 transporter, the absorbance of
NaAtm1 in detergent micelles was compared to that NaAtm1 in nanodiscs. It was observed that
the nanodisc samples showed a consistent 1.33-fold increase in absorbance when compared to
detergent-solubilized samples. Thus, using the calculated extinction coefficient of NaAtm1 alone,
the concentration of the NaAtm1-MSP1D1-lipid complex can be determined. For example, an
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absorbance value corresponding to 500 nM NaAtm1 in detergent would translate into 667 nM
NaAtm1 in nanodisc. This correction factor will be appropriate for quantification of samples for
functional assays.

3.7

Transition to an IMAC-based purification method
Unfortunately, the results seen in table 3-1 were not consistent across multiple tests. A

higher-than-expected result with a w/w ratio of ~1:3 was often seen. The most likely cause of this
in consistency was the presence of empty nanodisc (Peak 2) that was unable to be separated from
Peak 1 using size exclusion chromatography. To rectify this issue, size exclusion chromatography
was replaced by an IMAC-based purification method for the isolation of NaAtm1 nanodiscs
following reconstitution.
To isolate NaAtm1 nanodiscs from empty nanodiscs, the His-tag on MSP1D1 can be
removed via proteolytic cleavage. Using this strategy, NaAtm1 nanodiscs could bind to Ni-NTA
resin due to the His-tag on NaAtm1, but empty discs would remain unbound and removed from
the mixture (Figure 3-21).
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Figure 3-21. IMAC purification with MSP1D1 containing His-tag produces two products, both with His-tag. Cleavage of
the MSP1D1 His-tag results in one His-tagged product and one tagless product.

To remove the His-tag on MSP1D1, we took advantage of a TEV proteolytic cleavage site
between the His-tag and MSP1D1 coding sequence. Due to the high cost of commercially
available TEV, and the need for large quantities, we decided to express and purify TEV in-house.
Once available, the TEV: MSP1 reaction ratio was optimized, and subsequent purification of Histag-cleaved was performed.

3.8 Optimization of His-tag cleavage by TEV protease
TEV protease was purified as described in Chapter 2. Once purified, an initial test of
protease activity was conducted using MSP1D1. Manufacturers recommend 1 µg of commercially
available TEV protease for every 15 µg of target protein, which translates into approximately a
1:17 TEV: MSP1D1 molar ratio. To assess if lower amounts of TEV could be used to obtain
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efficient cleavage, four reactions were created with varying amounts of MSP1D1. In these
reactions, 1 µg of TEV protease was applied to 15 µg, 50 µg, 100 µg, and 200 µg of MSP1D1.
Samples of each reaction were taken immediately upon mixing and quickly flash frozen in liquid
nitrogen for analysis. The cleavage reactions were then allowed to proceed overnight at 4 °C. The
next day, samples were taken and analyzed via SDS-PAGE (Figure 3-22).

Figure 3-22. Cleavage reactions with varying ratios of TEV: MSP1D1. T0 = 0 hours, T1 = 24 hours.

The results showed that after 24 hours, both the 1:15 (w/w) and 1:50 (w/w) samples showed
complete cleavage of MSP1D1 (removal of upper band) while the 1:100 (w/w) showed almost
complete cleavage and the 1:200 (w/w) showed incomplete cleavage of MSP1D1 (presence of
upper band). From this test it was determined that using 1:50 (w/w) was the best ratio to use for
future reactions.

3.9 Preparation of His-tag-cleaved MSP1D1
After determining the proper ratio of TEV protease to MSP1D1, a method was created to
purify isolate cleaved MSP1D1 from uncleaved MSP1D1.
Following cleavage for 24 hours at 4 °C, reactions were purified by IMAC using Ni-NTA
resin. In this case however, the isolation process was somewhat unconventional. In most cases,
the target protein contains the His-tag and is retained on the column. A low concentration of
imidazole (15-25 mM) is present to prevent non-specific binding by contaminating proteins but
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also results in the loss of some target protein as well. This small loss of His-tagged target protein
is preferable to having contaminants in the final product. The His-tagged target protein is then
eluted at higher concentration imidazole, typically 350-400 mM. This general procedure was
applied to the purification of NaAtm1, MSP1D1, and TEV protease. In contrast, for purification
of the cleaved MSP1D1, the contaminating proteins are retained on the column, and the target
protein is collected in the “flow through” (Figure 3-23).

Figure 3-23. Normal IMAC vs Reverse IMAC

To optimize the final purity of the “flow through” which contains the target protein, the
imidazole level needs to be low enough that all unwanted his-tagged contaminants are retained on
the column, even at the loss of a small amount of target protein due to non-specific binding. To
determine the optimum imidazole concentration, 10 mM imidazole, 15 mM imidazole, and no
imidazole were added to cleavage reactions. Once the “flow through” was complete, the remaining
bound contaminant proteins were eluted using 350 mM Imidazole. Both “flow-through” and
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elution peaks were analyzed for the presence of His-tag cleaved MSP1D1. The results showed that
an imidazole concentration of 15 mM was ideal to prevent non-specific binding of cleaved
MSP1D1, and also retain the contaminant tagged MSP1D1 on the column. Ultimately, a large
amount of tagless MSP1D1 was recovered for subsequent reconstitutions.

Figure 3-24. Comparison of His-tag separations using 0 mM, 10 mM, and 15 mM imidazole. For each run a constant
concentration of noted imidazole was using during the “flow through”. Once complete, 350 mM imidazole was used
during an elution phase for analysis purposes.

3.10

Purification of NaAtm1 in MSP1D1 nanodisc using IMAC
Once purified, His-tag-cleaved MSP1D1 was used in the creation of large-scale

reconstitutions using the optimized molar ratio of 1-4-60 NaAtm1-MSP1D1-Lipid with a final
volume of 1 mL and a final NaAtm1 concentration of 5 µM.
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3.10.1 Assembly and purification of large-scale reconstitutions
Large-scale reconstitutions were created using the same procedure as described in section
3.3.2.1 with minor changes. These changes included replacing His-tagged MSP1D1 with His-tagcleaved MSP1D1, increasing the final volume from 300 µL to 1 mL, and increasing the Eppendorf
tube from 1.5 mL to 5 mL. It was normal for three to five 1 mL reconstitutions to be created at
once.
Following overnight incubation, reconstitutions were centrifuged at 3,500 rpm for 2
minutes to pellet the Bio-Beads. The reconstitution mixtures were then pooled and filtered using a
0.22 µm filter to remove aggregates. Imidazole was added to the filtered mixture to create a final
concentration of 15 mM. The sample was then flowed over a 1 mL HisTrap HP (Ni-NTA) column,
using the column in the traditional way to capture His-tagged full nanodisc (Figure 3-25). The
target protein was eluted and fractions collected. Pooled fractions were then concentrated to under
1.5 mL using a 100kDa concentrator before being injected over a 5 mL HiTrap Desalting column
to remove imidazole. Given this new method of purification, no size exclusion chromatography
was necessary. IMAC fractions were collected, aliquoted, and flash frozen in liquid nitrogen for
use and further analysis.
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Figure 3-25. IMAC chromatogram of nanodisc separation using a 1 mL HisTrap HP Ni-NTA column.

3.10.2 Analysis of large-scale reconstitutions
A 500 µL sample of the desalted protein was thawed and flowed over a Superdex 200
Increase 10/300 GL size exclusion column for confirmation of a single species. The results showed
a single peak around 12.1 mL (Figure 3-26). When compared to a small-scale reconstitution of 14-60 NaAtm1-MSP1D1-Lipid 300 µL, Peak 1 in the small-scale reconstitution overlaps nicely
with the single peak from the IMAC purified nanodisc, and the contaminating Peaks 2 and 3 are
completely removed (Figure 3-27). This suggests that the IMAC purification process works well
for the creation of ultra-pure NaAtm1 in MSP1D1 nanodisc.
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Figure 3-26. Full nanodisc from IMAC purification analyzed using SEC.

Figure 3-27. Comparison of IMAC separated nanodisc (blue) and small-scale 1-4-60 reconstitution.

3.11 Conclusion
In this Chapter I have described multiple structures that can be used to mimic a lipid bilayer
- the natural environment of NaAtm1 and ABC transporters in general. These structures include
detergent micelles, liposomes, and nanodiscs. Nanodiscs were chosen for studies with NaAtm1
due to their relative robustness compared to liposomes and their capacity to more closely mimic a
lipid bilayer than detergent micelles. Through iterative modifications of both reconstitution
component ratios and purification methods, I have created a method for the assembly of NaAtm1MSP1D1 complexed nanodiscs. Importantly, this system is scalable to the larger quantities needed
for future functional studies.
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CHAPTER 4
Preliminary Kinetic Assays and Future Work

4.1

Introduction
The ultimate goal of our NaAtm1 studies is to understand the molecular mechanism by

which this protein drives transport of substrates across lipid membranes. The incorporation of
NaAtm1 into nanodiscs is an important foundational step in this pursuit. While the structural
studies in detergent have provided a wealth of information on NaAtm1, careful kinetic and
thermodynamic assays in lipidic environments will significantly further our understanding of its
mechanism. Questions include: what is the natural substrate for NaAtm1, how quickly does
NaAtm1 transport this substrate, and what is the affinity for this substrate? Using both DDMsolubilized NaAtm1 and the newly-formed NaAtm1 nanodiscs, two preliminary experiments were
conducted.

4.2

Kinetic assays
First, the rate of ATP hydrolysis was measured as a function of ATP concentration. This

canonical experiment provides three key parameters when fit to a Michaelis-Menten model: (1)
the turnover number (kcat), which is the rate constant for ATP hydrolysis at saturating concentration
(2) the Michaelis constant (Km), which is the concentration of the substrate at which the turnover
rate is half the calculated maximum velocity, and (3) the Hill coefficient (n), which is a measure
of cooperativity between the two ATP sites. Using the system described in Chapter 2, the activity
of detergent-solubilized NaAtm1 was monitored in the absence of substrate. Best-fit values were
kcat = 14.42 min-1, Km = 36 µM, and n = 1.36. The latter value suggests that the binding of the first
ATP molecule to NaAtm1 increases the affinity for the second molecule, a feature that is common
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amongst ABC transporters. This experiment was consistent with published parameters, which had
a slightly lower turnover rate of 8.8 ± 0.8 min-1 at room temperature, while our data was collected
at 37 °C.
A few months later, however, the result was startlingly different, with a turnover rate of
~54 min-1. (Figure 4-1). During the troubleshooting process, all reagents were made fresh,
including the preparation of NaAtm1, however the results remained consistently 4-fold higher. It
is still unclear what has caused this dramatic change in activity and what it means for further kinetic
assays.

Figure 4-1. Comparison of the kobs for an initial assay (circle) and subsequent experiments (triangle).

Next, the kinetic activity of NaAtm1 nanodiscs was directly compared to NaAtm1 in
detergent. Surprisingly, the results were identical. Most ABC transporters show drastic inhibition
of uncoupled hydrolysis upon insertion into a lipid bilayer, and thus further experimentation will
determine if NaAtm1 is an exception to this case.
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kcat (min-1) Km (µM)
n
NaAtm1 in detergent:
54.19
238
1.896
NaAtm1 in nanodisc:
54.59
267
1.743
Figure 4-2. A) Kinetic assay for NaAtm1 in detergent. B) Kinetic assay for NaAtm1 in nanodisc. The kcat, Km, and n for
both assays are startlingly similar.

4.3

Future work
While my time at USF is at an end, this project still has many more avenues of inquiry.

Now that methods of purification and nanodisc assembly have been created, there is a solid
foundation for further work. Types of future experiments include further kinetic assays combined
with mutational analyses, and EPR or fluorescence spectroscopy tests.

4.3.1 Further kinetic assays
Detailed kinetic studies will yield important insights into the mechanism of NaAtm1, such
as the coordination between the two NBDs, substrate preferences, and the efficiency of transport.
While NaAtm1 mutants have not been discussed in this thesis, mutant constructs of NaAtm1 have
been created to help answer these questions. These are K400A (Walker A mutant to remove ability
to bind ATP), E523Q (Walker B mutant to remove ability to hydrolyze ATP), and K142Q (an
equivalent of R216Q [1] that should prohibit binding of the substrate GSSG). The incorporation
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of these mutants into kinetic assays, in addition to comparisons between detergent micelles and
nanodiscs, will allow us to further explore NaAtm1 function.
4.3.2 Detection of conformational changes
Currently, there is only one high-resolution crystal structure of NaAtm1, much like a single
snapshot of the enzyme in motion. To detect conformational changes that take place during the
transport cycle, a cysteine mutation was introduced which enables fluorescent labeling at the
reactive thiol side chain (NaAtm1 does not contain any naturally-occurring cysteines). Residue
S526 was selected as a labeling site because it is located in the NBDs, which is believed to move
substantially and is within the critical distance needed for use in fluorescence resonance energy
transfer (FRET) experiments. This technique will allow us to monitor changes in the relative
distance between the NBDs as a function of nucleotide-state and substrate binding. We could also
compare the flexibility of the protein in detergent micelles versus lipid bilayers. Furthermore, spinlabeling of the cysteine may allow us to follow these motions using electron paramagnetic
resonance spectroscopy, another technique that has been commonly used to detect conformational
changes in proteins. Lastly, introduction of cysteine residues at other locations will allow us to
construct a more complete picture of NaAtm1 conformations during the transport cycle.
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Figure 4-3. Side view (A) and bottom view (B) of the S526C mutation site (red) that will be used for FRET analysis
[2].

4.4

Conclusion
This thesis has detailed ABC transporters, their diversity, and their importance to human

health. It focuses on the ABCB-type importer NaAtm1 - an exporter shown to export the heavy
metals silver and mercury in vivo [2]. The main goal of this work was to create a robust lipidic
environment in which to study NaAtm1. This mimetic environment came in the form of nanodiscs
- a self-assembling lipid bilayer disc that surrounds NaAtm1.
To accomplish this, the purification of NaAtm1 and the scaffolding protein MSP1D1 were
conducted and optimized. Through careful and systematic modification of the nanodisc
components, an ideal reconstitution ratio of NaAtm1:MSP1D1:lipids was determined, and the
proper stoichiometry of 2 MSP1D1 per 1 NaAtm1 was verified. Additionally, an improved method
for the enrichment of NaAtm1 nanodiscs was developed based on affinity chromatography. This
work lays the foundation for future studies on elucidating the mechanism of NaAtm1 in a lipidic
environment.
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